Compositions and methods for treatment of presbyopia
Compositions with muscarinic agonists and cycloplegic agents stabilize aceclidine for effective presbyopia treatment, enhancing near vision while preserving distance vision and reducing side effects, achieving improved visual acuity and stability.
Patent Information
- Application Number
- JP2024126666
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2018-10-10
- Filing Date
- 2024-08-02
- Publication Date
- 2024-11-06
- Estimated Expiration
- 2039-10-08
AI Technical Summary
Current treatments for presbyopia, such as miotics and surgical procedures, often cause significant side effects like decreased distance vision, cyclospasm, and retinal detachment risks, and require complex formulations and storage conditions.
Compositions comprising muscarinic agonists that preferentially activate M1 and M3 muscarinic acetylcholine receptors, combined with cycloplegic agents and cryoprotectants, stabilize aceclidine for improved near vision without compromising distance vision, using specific concentration ratios and storage conditions.
The compositions provide enhanced near vision with minimal side effects, maintaining distance vision and reducing cyclospasm, with stability up to 7 months, and improve visual acuity by 3-10 lines, suitable for both day and night use.
Smart Images

Figure 2024156863000001_ABST
Abstract
Description
[Background technology]
[0001] As people age, the minimum distance from the eye at which an object can be focused increases if the person has corrected or excellent unaided distance vision. For example, a 10-year-old child may be able to focus on an object or "focal point" only 3 inches (0.072 meters) from the eye while maintaining excellent distance vision, whereas a 40-year-old may be able to focus at 6 inches (0.15 meters), and a 60-year-old may be able to focus at a poor 39 inches (1.0 meters). This condition of increased minimum focusing distance for individuals with excellent unaided distance vision is called presbyopia, loosely translated as "farsightedness."
[0002] Excellent unaided distance vision is also known as emmetropia. The inability to focus at a distance is known as myopia, and the inability to focus at a close distance is known as hyperopia. Specifically, "distance" vision is considered to be a focus more than one meter away from the eye, and near vision is considered to be a focus less than one meter away from the eye. The minimum focal distance at which an object is in focus is called the "near point." The change in focus from distance to near point and any focus in between is called accommodation. Accommodation is often measured in diopters. Diopters are calculated by taking the reciprocal of the focal length (in meters). For example, the decrease in accommodation from a 10-year-old eye to a 60-year-old eye is about 13 diopters (1÷0.072 meters=13.89 diopters; 1÷1 meter=1 diopter).
[0003] The highest incidence of first complaints of presbyopia occurs in people aged 42-44 years. Presbyopia occurs due to a decrease in the eye's ability to accommodate using near-reflex pupillary constriction as a person ages, resulting in a decrease in ocular convergence, especially the contraction of the ciliary muscles. This decrease in accommodation results in an inappropriate change in the normal thickening and increase in curvature of the anterior surface of the lens, which is necessary for the shift of focus from distant objects to near objects. Important near-focus tasks affected by presbyopia include viewing computer screens (21 inches) and reading print (16 inches).
[0004] Presbyopia is a normal and inevitable effect of aging, and for many people in their 40s, it is the first unmistakable sign of getting older. According to one study, more than one billion people worldwide had presbyopia in 2005. This same study predicted that number would nearly double by 2050. If everyone over the age of 45 were considered presbyopic, an estimated 122 million people in the United States alone had presbyopia in 2010. This number will only increase as the baby boomer generation reaches menopause.
[0005] Presbyopia has symptoms that occur when the ability that once occurred almost instantly to function quickly in many tasks that require focusing at both far and near points becomes limited. In presbyopic patients, these tasks can only be performed by using glasses, contact lenses, or after undergoing invasive surgery. One such optical correction, the monovision method, can be performed by using glasses, contact lenses, or even surgery. Monovision corrects one eye for near focus and the other eye for far focus. However, monovision correction is usually accompanied by a decrease in depth perception and distance vision, especially in dim light (e.g., at night). Other surgical procedures developed to alleviate presbyopia include: (1) insertion of an intraocular lens (INTRACOR®; a registered trademark of Technolas Perfect Vision GMBH); (2) corneal reshaping (PresbyLASIK and conductive keratoplasty); (3) expansion of the scleral band; and (4) insertion of a corneal inlay (FlexivueMicrolens®; a registered trademark of PresbyBio LLC, Kamra®; a registered trademark of AcuFocus, Inc. and Vue+). The Kamra® corneal inlay, manufactured by AcuFocus, works by fitting a pinhole into the cornea to increase the depth of focus.
[0006] Similar effects can be achieved with common miotics such as pilocarpine (a nonselective muscarinic acetylcholine receptor agonist), carbachol (a nonselective muscarinic acetylcholine receptor agonist), and phosphodiesterase inhibitors. These common miotics induce a pinhole pupil at concentrations sufficient to achieve a pupil smaller than 2.0 mm and may extend the depth of focus like an inlay, but at concentrations sufficient to cause a pinhole pupil diameter of 2.0 mm or less, these agents cause increased ciliary muscle contraction, inducing accommodation of the remaining reserve, improving near vision at the expense of distance vision in individuals who still retain accommodation function. Side effects of ciliary spasm, as seen with pilocarpine, include migraines such as pain at the supraorbital rim, as well as blurred hyperopia resulting from induced myopia beyond the ability of the pinhole pupil to correct, so weaker concentrations with much shorter action and more marginal effects must be used. In such cases, even slight hyperopia helps to offset the induced myopia, but quite often even a very small increase in myopia makes it worse. In extreme cases, such ciliary muscle spasms are associated with shallowing of the anterior chamber, pulling on the ora serrata of the retina, which can result in retinal tears and / or retinal detachment.
[0007] Miotics have been described in various patents and patent applications for the treatment of presbyopia. U.S. Patent Nos. 6,291,466 and 6,410,544 describe the use of pilocarpine to modulate the contraction of the ciliary muscle to return the eye to a resting state and potentially restore its accommodative capabilities.
[0008] US Patent No. 8,299,079 (HEK Development LLC) describes the use of direct acting general miotics such as pilocarpine, carbachol, and phospholipid iodide with the alpha 2 selective vasoconstrictor brimonidine at concentrations of 0.05% to 3.0% w / v. However, use of brimonidine concentrations of about 0.20% (or anything above 0.05%) w / v induces ciliary spasm, often accompanied by migraine intensity brow supraorbital pain and / or headache, often resulting in increased rebound hyperemia. For example, rebound hyperemia occurs in 25% of patients using brimonidine 0.20% w / v (Alphagan®, a registered trademark of Allergan, Inc.) twice daily.
[0009] US Patent Application Publication No. 2014 / 0113946 describes the use of the vasoconstrictors oxymetazoline and pilocarpine, an alpha 1 and mild alpha 2 agonist, with limited distance sharpness and duration (Table 1). Of the 16 eyes treated, only 3 were -0.25 to -0.50 diopters, and 8 were mildly hyperopic. Of the -0.50 diopter eyes, 2 were reduced to a distance of 20.40. Furthermore, the duration was limited, as the full effect began to diminish in approximately 4 hours. Pupil size ranged from 2.0 mm to 2.7 mm, with little improvement in near effect and distance sharpness from depth of focus.
[0010] All these attempts at miosis treatment of presbyopia induce a transient myopia of several diopters, compromising near vision improvement for the entire duration of their action (usually lasting several hours) and worsening distance vision to near legal blindness or worse. This myopic effect is amplified by an exponential decrease in distance vision for even a small increment of nominal myopia with respect to untreated unaided vision. For example, a patient who is normally mildly myopic with respect to distance vision without glasses (e.g., -0.25D, -0.50D spherical equivalent) typically loses several lines of distance vision (i.e., -0.75D spherical equivalent) after instillation of 1% pilocarpine.
[0011] Miotics traditionally used to treat glaucoma other than pilocarpine, especially aceclidine, are also associated with ciliary spasm, pain and / or headache at the supraorbital rim, and myopic blurring. Furthermore, aceclidine is unstable in solution. Usually, aceclidine is stored in a two-bottle system (one bottle containing lyophilized aceclidine and a second bottle containing the diluent required to reconstitute the lyophilized aceclidine before topical instillation). However, the main problem with its use as a presbyopic miotic is that it is painful and, in some cases, may induce far-distance blurring.
[0012] No. 9,089,562 describes a composition comprising aceclidine in combination with a cycloplegic drug, in a preferred embodiment aceclidine 1.45% is combined with tropicamide 0.042%. The addition of a cycloplegic drug at very low concentrations (less than 0.10%) surprisingly produces pupil constriction and allows for improvement in useful distance and near vision without ciliary muscle spasm (a very painful and potentially disabling migraine like supraorbital rim pain) that is induced by the use of aceclidine alone. In addition, aceclidine and cycloplegic drugs require specific narrowly defined ratios and concentration ranges that are interrelated, such as the complicating factors in the manufacturing and regulatory processes, particularly the need for freeze-drying of aceclidine to enable stable storage, and the accompanying effect of cryoprotectants / lyoprotectants (hereinafter referred to as "cryoprotectants"), and as the discovery of the present invention, the addition of cryoprotectants such as polyols in the mannitol of the preferred embodiment results in a decrease in the effectiveness of the defined ranges and concentration ratios of U.S. Patent No. 9,089,562. Due to these medical and practical inefficiencies, aceclidine compositions have been found that require the same or slightly higher concentrations of aceclidine than U.S. Patent No. 9,089,562, and much lower concentrations, or in some cases no cycloplegic drugs, while allowing the modification of the formulation to freeze-dry aceclidine would be favorable for the treatment of presbyopia with the required commercially stable formulation. However, to date, aceclidine compositions containing cycloplegic agents in amounts less than those claimed in the United States have not been effective in treating presbyopia with aceclidine alone, as discussed above, particularly in young and middle-aged presbyopia (ages 45-58), due to severe cyclospasm, and may cause accommodatively induced hyperopic blur in some subjects. [Prior art documents] [Patent documents]
[0013] [Patent Document 1] U.S. Patent No. 6,291,466 [Patent Document 2] U.S. Patent No. 6,410,544 [Patent Document 3] U.S. Patent No. 8,299,079 [Patent Document 4] US Patent Application Publication No. 2014 / 0113946 [Patent Document 5] U.S. Pat. No. 9,089,562 Summary of the Invention [Problem to be solved by the invention]
[0014] Thus, there is a need in the art for a convenient treatment for presbyopia that is non-invasive and has minimal side effects.Specifically, there is a need for an ophthalmic composition that allows presbyopic patients to focus on nearby objects without significant side effects such as reduced vision, blurred vision, pain, redness, impaired night driving or reduced vision in dim light, induction of nasal congestion, or risk of retinal detachment.Furthermore, there is a need in the art for a reduction or elimination of the need for cycloplegic agents used with aceclidine to potentially enhance duration and efficacy, as well as a means of storage of a stable aceclidine composition, such a composition preferably enhancing both the distance and near depth of focus, and pupillary miosis in the range of 1.50-2.0 mm, without clinically significant side effects. [Means for solving the problem]
[0015] In certain embodiments, the present invention relates to compositions and methods for the treatment of presbyopia.
[0016] In certain embodiments, the present invention relates to compositions and methods for the treatment of presbyopia comprising a muscarinic agonist that preferentially activates M1 and M3 muscarinic acetylcholine receptors. In even more preferred embodiments, the muscarinic agonist is more highly selective for M1 over M3. In certain embodiments, the present invention relates to compositions and methods for the treatment of presbyopia comprising a muscarinic agonist that preferentially activates M1 and M3 muscarinic acetylcholine receptors.
[0017] In certain embodiments, the present invention relates to compositions and methods for the treatment of presbyopia comprising a muscarinic agonist selected from the group consisting of aceclidine, talsaclidine, sabcomeline, cevimeline, WAY-132983, AFB267B (NGX267), AC-42, AC-260584, 77-LH-28-1, and LY593039 or pharma-ceutically acceptable salts, esters, analogs, prodrugs, or derivatives thereof.
[0018] In certain embodiments, the present invention relates to compositions and methods for the treatment of presbyopia comprising muscarinic agonists that activate only the M1 muscarinic acetylcholine receptor.
[0019] In certain other embodiments, the present invention relates to ophthalmic compositions for the treatment of presbyopia comprising aceclidine.
[0020] In certain preferred embodiments, the present invention relates to an ophthalmic composition for the treatment of presbyopia comprising aceclidine, preferably in a concentration of about 0.25% to about 2.0% w / v, and a cycloplegic agent, preferably tropicamide.
[0021] In certain preferred embodiments, the present invention is directed to an ophthalmic composition for the treatment of presbyopia comprising aceclidine, preferably at a concentration of about 0.25% to about 2.0% w / v, and a cryoprotectant, preferably a polyol, preferably mannitol at a concentration of about 1.0% to about 10.0% w / v, more preferably 2.5% w / v. In certain preferred embodiments, the present invention relates to an ophthalmic composition for the treatment of presbyopia comprising about 1.75% w / v aceclidine; about 2.5% w / v mannitol; and, optionally, about 0.004% to 0.015% w / v tropicamide.
[0022] In certain preferred embodiments, the present invention relates to an ophthalmic composition for the treatment of presbyopia comprising about 1.75% w / v aceclidine; about 2.5% w / v mannitol; about 1.0% to about 6.0% w / v of a non-ionic surfactant; about 0.1% to about 2.25% w / v hydroxypropyl methylcellulose; and, optionally, about 0.004% to 0.015% w / v tropicamide.
[0023] In certain preferred embodiments, the present invention provides a composition comprising about 1.75% w / v aceclidine; about 2.5% w / v mannitol; and about 1.0% to about 6.0% w / v of a non-ionic surfactant, preferably a polysorbate, tyloxapol, poloxamer, cyclodextrin, vitamin E. the present invention relates to an ophthalmic composition for the treatment of presbyopia comprising: TPGS and a polyoxyl, more preferably selected from polysorbate 80, even more preferably from about 1.0% to about 5.0% w / v of polysorbate 80, and most preferably from about 2.0% to about 4.0% w / v of polysorbate 80; from about 0.1% to about 2.25% w / v of hydroxypropyl methylcellulose, more preferably from about 0.75% to about 1.5% w / v of hydroxypropyl methylcellulose, and most preferably from about 1.0% to about 1.25% w / v of hydroxypropyl methylcellulose; from about 0.10% to about 0.12% w / v of sorbic acid; from about 0.005% to about 0.02% w / v of benzalkonium chloride; and, optionally, from about 0.004% to 0.015% w / v of tropicamide.
[0024] In certain preferred embodiments, the present invention provides a composition comprising about 1.75% w / v aceclidine; about 2.5% w / v mannitol; a non-ionic surfactant, preferably the non-ionic surfactant is selected from polysorbate, tyloxapol, poloxamer, cyclodextrin, vitamin E TPGS, and polyoxyl, more preferably polysorbate 80, even more preferably from about 1.0% to about 5.0% w / v polysorbate 80, and most preferably from about 2.0% to about 4.0% w / v polysorbate 80; about 0.1% to about 2.25% w / v hydroxypropyl methylcellulose, more preferably from about 0.75% to about 1.5% w / v hydroxypropyl methylcellulose, and most preferably from about 1.0% to about 1.25% w / v hydroxypropyl methylcellulose; about 0.10% The present invention relates to an ophthalmic composition for the treatment of presbyopia, comprising: about 0.12% w / v sorbic acid; about 0.005% to about 0.02% w / v benzalkonium chloride; one or more antioxidants selected from the group consisting of ethylenediaminetetraacetic acid (EDTA), ethylenediaminetetraacetic acid dihydrate, sodium citrate, and citrate buffer, preferably selected from the group consisting of ethylenediaminetetraacetic acid dihydrate and sodium citrate or citrate buffer; and, optionally, about 0.004% to 0.015% w / v tropicamide.
[0025] In certain preferred embodiments, the present invention relates to an ophthalmic composition for the treatment of presbyopia comprising about 1.75% w / v aceclidine; optionally, about 0.004% to 0.015% w / v tropicamide; about 1.0% to about 6.0% w / v nonionic surfactant; about 0.1% to about 2.25% w / v hydroxypropyl methylcellulose; about 0.10% to about 0.12% w / v sorbic acid; and about 0.005% to about 0.02% w / v benzalkonium chloride, wherein the composition is maintained at a temperature of about 2 degrees Celsius to about 8 degrees Celsius.
[0026] In certain preferred embodiments, the present invention relates to an ophthalmic composition for the treatment of presbyopia comprising about 1.75% w / v aceclidine; about 2.5% w / v mannitol; about 4.0% w / v polysorbate 80; about 1.25% w / v hydroxypropyl methylcellulose; about 0.12% w / v sorbic acid; about 0.1% w / v ethylenediaminetetraacetic acid dihydrate; about 0.02% w / v benzalkonium chloride; and about 0.1% w / v sodium citrate or citrate buffer.
[0027] In certain preferred embodiments, the present invention relates to an ophthalmic composition for the treatment of presbyopia comprising about 1.75% w / v aceclidine; about 2.5% w / v mannitol; about 4.0% w / v polysorbate 80; about 1.25% w / v hydroxypropyl methylcellulose; about 0.12% w / v sorbic acid; about 0.1% w / v ethylenediaminetetraacetic acid dihydrate; about 0.02% w / v benzalkonium chloride; about 0.1% w / v sodium citrate or citrate buffer; and about 0.01% w / v tropicamide.
[0028] In a preferred embodiment, the concentration of hydroxypropyl methylcellulose is about 0.1% to about 2.25% w / v, more preferably about 0.75% to about 1.5% w / v, and most preferably about 1.0% to about 1.25% w / v. Preferably, the concentration of hydroxypropyl methylcellulose is such that the viscosity before instillation is about 1 to about 10,000 cps, more preferably about 200 to about 500 cps, and most preferably about 400 cps.
[0029] In another preferred embodiment, the ophthalmic composition of the present invention comprises one or more antioxidants selected from the group consisting of ethylenediaminetetraacetic acid ("EDTA"), ethylenediaminetetraacetic acid dihydrate, sodium citrate and citrate buffer, preferably 0.1% w / v ethylenediaminetetraacetic acid dihydrate; and 0.1% w / v sodium citrate or citrate buffer.
[0030] In another preferred embodiment, the non-ionic surfactant is selected from polysorbates, tyloxapol, poloxamer, cyclodextrin, Vitamin E TPGS, and polyoxyls, preferably polysorbate 80, more preferably 4.0% w / v polysorbate 80.
[0031] In another preferred embodiment, the ophthalmic compositions of the present invention have a pH of about 4.0 to about 8.0 for compositions not containing tropicamide, about 4.0 to about 6.0 for compositions containing tropicamide, and more preferably, 5.0 for compositions regardless of tropicamide content.
[0032] In another preferred embodiment, the present invention provides a method for the preparation of a cellular endothelial cell comprising the steps of: aceclidine, preferably at a concentration of about 0.25% to about 2.0% w / v; a cryoprotectant, preferably a polyol, preferably at a concentration of about 1.0% to about 10.0% w / v, more preferably 2.5% w / v, of mannitol; and a non-ionic surfactant (preferably, the non-ionic surfactant is a polysorbate, polyoxyl castor oil, polyoxyl stearate, poloxamer, polyethylene glycol, polyoxyl stearate ... The present invention relates to an ophthalmic composition for the treatment of presbyopia comprising a glycerol-containing ethyl ether, a glycerol-containing ethyl ether, a tyloxapol, and 2-[[10,13-dimethyl-17-(6-methylheptan-2-yl)-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]ethanol, more preferably selected from the group consisting of polysorbate 80 or polyoxyl 35 castor oil.
[0033] In another preferred embodiment, the present invention provides a composition comprising aceclidine, preferably at a concentration of about 0.25% to about 2.0% w / v, more preferably 1.75% w / v; a cryoprotectant, preferably a polyol, preferably at a concentration of about 1.0% to about 10.0% w / v, more preferably mannitol at a concentration of 2.5% w / v; tropicamide, preferably at a concentration of about 0.004% to about 0.025% w / v, more preferably about 0.005% to about 0.007%; a non-ionic surfactant, preferably polysorbate 80, more preferably at a concentration of about 0.5% to about 10.0% w / v, more preferably about 2.0% to about 6.0% w / v, even more preferably about 2.5% to about 4.0% w / v; and preferably a cellulose derivative, hyaluronic acid, carbomer and gum, more preferably high molecular weight carboxymethylcellulose. or Carbomer 940, preferably at a concentration of about 1.0% to about 2.0% w / v, more preferably about 1.35% to 1.45% w / v, even more preferably about 1.42% w / v, or other viscosity agents such as hydroxypropyl methylcellulose, preferably at a concentration of about 1.0% to about 2.0%, more preferably about 0.50% to 1.95%, wherein the initial viscosity of the composition prior to instillation in the eye may range from about 25 to about 10,000 centipoise, more preferably about 100 to about 5000 centipoise, and wherein the composition is a non-Newtonian fluid or induces tear production resulting in minimal blurring, or may be associated with minimal blurring at high (within a blink) versus low (between blinks) shear after instillation.
[0034] In certain preferred embodiments, the present invention provides a method for the preparation of a cryoprotectant, preferably an aceclidine, at a concentration of about 0.25% to about 2.0% w / v, more preferably 1.75% w / v; a cryoprotectant, preferably a polyol, at a concentration of about 1.0% to about 10.0% w / v, more preferably 2.5% w / v mannitol; a non-isopropyl alcohol, preferably an iodine-containing alcohol, at a concentration of about 0.004% to about 0.025% w / v, more preferably about 0.005% to about 0.007%; an ionic surfactant, preferably polysorbate 80, more preferably at a concentration of about 0.5% to about 10.0% w / v, more preferably about 2.0% to about 6.0% w / v, even more preferably about 2.5% to about 4.0% w / v; a viscosity agent, preferably selected from the group consisting of cellulose derivatives, hyaluronic acid, carbomer 940 and gums, more preferably high molecular weight carboxymethylcellulose or carbomer 940, preferably at a concentration of about 1.0% to about 2.0% w / v; % to about 2.0% w / v, more preferably about 1.35% to 1.45% w / v, even more preferably about 1.42% w / v, or other viscosity agents such as hydroxypropyl methylcellulose, preferably at a concentration of about 0.5% to about 1.75%, and more preferably about 0.75% or 1.5%, most preferably about 1.0% to about 1.5%, and most preferably about 1.05% to 1.25%, where the initial viscosity of the composition prior to instillation in the eye is increased by the addition of an ophthalmic solution. The present invention relates to an ophthalmic composition for the treatment of presbyopia, the composition having a refractive index ranging from about 25 to about 10,000 centipoise, more preferably from about 100 to about 5000 centipoise, being a non-Newtonian fluid, exhibiting minimal blurring at high shear (within a single blink) and low shear (between blinks) after instillation, and preferably comprising a preservative selected from the group consisting of benzalkonium chloride ("BAK"), sorbic acid, and oxychloro complexes.
[0035] In certain other embodiments, the present invention relates to a method of stabilizing a composition comprising aceclidine, comprising storing the composition in a container having a headspace at a temperature of about 2°C to about 8°C, preferably about 5°C.
[0036] In certain other embodiments, the compositions of the present invention are filled into a container having a headspace under an inert gas overlay, preferably nitrogen, and preferably the headspace is purged with an inert gas overlay, preferably nitrogen.
[0037] In certain other embodiments, the present invention relates to a method of stabilizing a composition comprising aceclidine, a viscosity agent, and a non-ionic surfactant comprising storing the composition in a container having a headspace at a temperature of about 2° C. to about 8° C., wherein the composition is filled into the container under a nitrogen overlay, the headspace is purged with nitrogen, and the composition provides a low shear (1 / sec) viscosity of about 50 to about 1000 centipoise and a high shear (1:1000 / sec) viscosity of about 0.5 centipoise or less.
[0038] In certain other embodiments, the container of the present invention comprises a closure and a container, a portion of the closure and a portion of the container being sealed with a leaching-resistant material selected from the group consisting of biaxially oriented polyethylene terephthalate, polytetrafluoroethylene, and aluminum foil, preferably biaxially oriented polyethylene terephthalate.
[0039] In certain other embodiments, the container of the present invention is placed within a second container formed or lined with a leaching-resistant material selected from the group consisting of biaxially oriented polyethylene terephthalate, polytetrafluoroethylene, and aluminum foil, preferably biaxially oriented polyethylene terephthalate.
[0040] In certain other embodiments, the invention relates to a method of stabilizing a composition comprising aceclidine comprising storing the composition in a container having a headspace at a temperature of about 22° C. to about 25° C., wherein the container comprises a closure and a container, a portion of the closure and a portion of the container being sealed with a leach-resistant material selected from the group consisting of biaxially oriented polyethylene terephthalate, polytetrafluoroethylene, and aluminum foil, and / or the container is placed in a second container formed from or lined with biaxially oriented polyethylene terephthalate, polytetrafluoroethylene, and aluminum foil.
[0041] In certain other embodiments, the second container includes a second closure, the second closure providing an air-tight seal.
[0042] In certain other embodiments, the hermetic seal is resealable.
[0043] In certain other embodiments, the aceclidine is at a concentration of about 0.25% to about 4.0% w / v aceclidine.
[0044] In certain other embodiments, the methods of the invention provide at least 90% stability of aceclidine for at least 7 months, at least 8 months, at least 12 months, at least 15 months, at least 18 months, at least 20 months, or at least 22 months.
[0045] In certain other embodiments, the compositions of the present invention further comprise a viscosity agent, a polysorbate, a cryoprotectant, and a preservative.
[0046] In certain other embodiments, the viscosity agent provides a viscosity of at least 50 centipoise, at least 100 centipoise, or at least 200 centipoise.
[0047] In certain other embodiments, the cryoprotectant is selected from the group consisting of polyols, sugars, alcohols, lower alkanols, lipophilic solvents, hydrophilic solvents, bulking agents, solubilizers, surfactants, antioxidants, cyclodextrins, maltodextrins, colloidal silicon dioxide, polyvinyl alcohol, 2-methyl-2,4-pentanediol, cellobiose, gelatin, polyethylene glycol (PEG), dimethyl sulfoxide (DMSO), formamide, antifreeze protein 752, or combinations thereof.
[0048] In certain other embodiments, the preservative is selected from the group consisting of benzalkonium chloride, sorbates, antioxidants, and combinations thereof.
[0049] In certain other embodiments, the antioxidant is selected from the group consisting of sodium ascorbate, sodium bisulfate, sodium metabisulfite, n-acetylcysteine, or combinations thereof.
[0050] In certain other embodiments, the present invention relates to a method of stabilizing a composition comprising aceclidine, hydroxypropyl methylcellulose, polysorbate 80, mannitol, sorbate, and an antioxidant selected from the group consisting of sodium ascorbate, sodium bisulfate, sodium metabisulfite, n-acetylcysteine, or combinations thereof, comprising storing the composition in a container having a headspace at a temperature of about 2 degrees Celsius to about 8 degrees Celsius, wherein the composition is filled into the container under an inert gas overlay, preferably nitrogen, and the headspace is purged with an inert gas, preferably nitrogen.
[0051] In certain other embodiments, aceclidine is at a concentration of about 0.25% to about 4.00% w / v, hydroxypropyl methylcellulose is at a concentration of about 0.75% to about 1.25% w / v, polysorbate 80 is at a concentration of about 2% to about 4% w / v, mannitol is at a concentration of about 2% to about 4% w / v, sorbate is at a concentration of about 0.10% to about 0.12% w / v, and the antioxidant is at a concentration of about 0.10% to about 0.25% w / v.
[0052] In certain other embodiments, the present invention relates to a container containing aceclidine prepared by a process comprising the steps of: a) Provide a container. b) Under an inert gas overlay, preferably nitrogen, the container is filled with the composition comprising aceclidine. c) The headspace created during filling step b) is purged with an inert gas, preferably nitrogen. d) Cover the container; and e) Optionally, storing the container at a temperature of about 2 to about 8°C.
[0053] In certain other embodiments, the present invention relates to one or more means for stabilizing the composition selected from the group consisting of about 0.25% to about 4.0% w / v aceclidine, filling the composition into a container under an inert gas overlay and purging the head space created during filling with the inert gas, having a total viscosity of the composition of at least 50 centipoise, adding a preservative to the composition selected from the group consisting of sorbate, benzalkonium chloride, sodium ascorbate, sodium bisulfate, sodium metabisulfite, n-acetylcysteine, and combinations thereof, wherein the composition is stored at a temperature of about 2° C. to about 8° C., and w / v refers to weight by total volume of the composition.
[0054] In certain other embodiments, the present invention relates to a method of treating presbyopia comprising administering to a subject in need thereof a composition of the present invention.
[0055] In certain other embodiments, the present invention relates to a method of treating presbyopia, comprising administering to a subject in need thereof an ophthalmic composition of the present invention, wherein the subject's near visual acuity is found to be improved to about 4 lines of resolution or better for at least 8 hours when the addition of 0.50% to 10%, more preferably 1.0% to 6.0%, and even more preferably 3.0% to 5.0% non-ionic surfactant is found; and, Optionally, improved by one or more of the following: In a preferred embodiment, an increase in viscosity such as about 400 cps using hydroxypropyl methylcellulose at 1.25%; And, the addition of a preservative combination of BAK, sorbate, and one or more antioxidant combinations of EDTA and citrate; This may result in one or more of the following further improvements: i) Reducing congestion; ii) An increase in lines that is nearly improved without any blurring of distance; iii) excellent comfort; and iv) Extension of Time.
[0056] In certain other embodiments, the present invention relates to a method of treating ocular refractive error in a subject in need thereof, comprising administering to the subject in need thereof a pharma- ceutically acceptable amount of a composition of the present invention, wherein the ocular refractive error is selected from presbyopia, myopia, hyperopia, astigmatism, or a combination thereof.
[0057] In certain other embodiments, the present invention relates to a method of treating refractive error of the eye, comprising administering to a patient in need thereof a pharma- ceutically acceptable amount of a composition of the present invention, Here, the size of the pupil is reduced to about 1.5 to about 2.5 mm, preferably about 1.7 to about 2.2 mm, and wherein the refractive error is selected from the group consisting of: The range of distance-corrected visual acuity is Mild to moderate hyperopia of 3.0 D or less; -Mild to moderate myopia of 5.0D or less; Regular astigmatism of 3.0 D or less; Uncorrected distance visual acuity when emmetropia is +0.50 to -0.50spheq and normal astigmatism is 0.75D or less; Irregular corneal astigmatism, ectasia-induced corneal irregularities, transparent-induced corneal irregularities, higher order aberrations, and refractive surgery-induced higher order aberrations.
[0058] The present invention further relates to a method for increasing visual depth of field (i.e., depth of focus) secondary to pupil constriction, comprising administering to a subject in need thereof a pharma- tically effective amount of the ophthalmic composition of the present invention.
[0059] The present invention further relates to a method of reducing the side effects of ophthalmic aceclidine administration by modulating the agonist effect on the ciliary body of the eye such that ciliary spasm, ciliary-induced brow pain, and / or ciliary-induced headache are substantially reduced or eliminated.
[0060] The present invention further relates to a method for enabling physiological local pre-symptomatic correction of both eyes.
[0061] The present invention further relates to a method for eliminating the need for monocular restriction due to distance blur or reducing the treatment of mild hyperopia to alleviate induced myopic blur, typically involving pilocarpine or a combination of pilocarpine and an alpha agonist.
[0062] The present invention further relates to a method of improving near vision by increasing accommodation without reducing distance vision sharpness, which is accomplished by simultaneously increasing the modulated incremental accommodation sufficient to provide additional near vision enhancement while preserving the induction rate and overall degree of accommodation such that the associated myopic blur does not impair the ability of the simultaneously induced pupillary constriction pinhole effect to filter refractive error and maintain distance sharpness.
[0063] The present invention further relates to a method of increasing visual depth perception in improving unaided near vision comprising administering to a subject in need thereof a pharma- tically effective amount of the ophthalmic composition of the present invention to both eyes (binocular vision), wherein such binocularity further enhances myopia beyond that of either eye separately.
[0064] The present invention is further directed to a method of improving vision in a subject having refractive error (vision error), comprising administering to a subject in need thereof a pharma- tically effective amount of a composition of the present invention.
[0065] The present invention further relates to a method of improving vision in a subject having a refractive error comprising administering to a subject in need thereof a pharma- tically effective amount of a composition of the present invention, wherein the refractive error is selected from the group consisting of myopia, hyperopia, regular astigmatism, irregular astigmatism and high regular astigmatism.
[0066] The present invention further relates to eliminating optical aberrations induced by corneal irregularities (astigmatism), opacities or very high regular astigmatism, including areas adjacent or peripheral to the central 1.5 mm optical zone, and thereby inducing improved visual acuity and quality of vision by filtering out these aberrations visually in people who suffer from irregular astigmatism or higher regular astigmatism such as occurs in conditions such as keratoconus, photorefractive keratectomy induced corneal opacities, interlaminar keratitis ("DLK") (post-LASIK DLK), other iatrogenically induced corneal irregularities such as cataract incisions, glaucoma filtering blebs, implanted glaucoma valves, corneal inlays with or without removal, ectasia after corneal surgery (LASIK) and corneal ectasia due to infection.
[0067] The present invention further aims to improve visual acuity compared to existing uncorrected refractive error. With this improvement in visual acuity, patients who currently require toric contact lenses for astigmatism, which are less comfortable and may shift with every blink, will often only require non-toric soft contact lenses or no contact lenses. Additionally, those who require air permeable contact lenses may no longer require contact lenses or only soft contact lenses, which are much more comfortable. Patients with high levels of astigmatism may no longer require correction or may need reduced astigmatism correction. Patients with mild to moderate levels of myopia may require less correction or may no longer require correction. Patients with mild to moderate levels of hyperopia (farsightedness) may no longer require correction or may need reduced correction.
[0068] The present invention relates to methods and ophthalmic compositions for improving vision. In a preferred embodiment, the present invention relates to methods and ophthalmic compositions for the treatment of presbyopia. In a more preferred embodiment, the present invention relates to ophthalmic compositions comprising aceclidine.
[0069] The present invention relates to methods and ophthalmic compositions for improving vision. In a preferred embodiment, the present invention relates to methods and ophthalmic compositions for the treatment of presbyopia. In a more preferred embodiment, the present invention relates to ophthalmic compositions comprising aceclidine.
[0070] The present invention relates to a method for treating irregular astigmatism, ectasia, and low myopia or hyperopia, with or without astigmatism, comprising administering to a subject in need thereof an ophthalmic composition of the present invention.
[0071] The present invention further relates to a method for stabilizing aceclidine, comprising a first chamber containing about 1.75% w / v aceclidine and about 2.5% w / v mannitol, and a second chamber containing about 0.01% w / v tropicamide, about 4.0% w / v polysorbate 80, about 1.25% w / v hydroxypropyl methylcellulose, about 0.10%-0.12% w / v sorbic acid, about 0.1% w / v ethylenediaminetetraacetic acid dihydrate, about 0.02% w / v benzalkonium chloride, and about 0.1% w / v sodium citrate or citrate buffer, wherein upon mixing of the first composition and the second composition, the efficacy of the aceclidine is maintained for at least one month.
[0072] The present invention further relates to a method of stabilizing aceclidine comprising storing the composition of the present invention at 0 degrees Celsius to 8 degrees Celsius.
[0073] The present invention further comprises: providing an ophthalmic composition comprising about 1.75% w / v aceclidine, about 2.5% w / v mannitol, about 0.01% w / v tropicamide, about 4.0% w / v polysorbate 80, and about 1.25% w / v hydroxypropyl methylcellulose; adding about 0.10% to 0.12% w / v sorbic acid; and adding one or more of about 0.1% w / v ethylenediaminetetraacetic acid dihydrate and about 0.1% w / v sodium citrate or citrate buffer; The present invention relates to a method for inhibiting the growth of microorganisms and fungi comprising: [Brief description of the drawings]
[0074] [Figure 1] 1 is a graphical representation of the effect of pilocarpine and aceclidine with or without tropicamide and with or without carrier on near and distance visual acuity in patients aged 45 years and older. [Diagram 2] This is a graph showing the effect of adding a non-ionic surfactant and a viscosity agent on near vision and duration of effect. Line-Hours indicates the line that improved duration of effect. [Diagram 3] This is a graphical representation of the efficacy index of formulations #L33 to #L94. The color of the box indicates the comfort level with white being good, cross-hatched being normal, and black being poor. [Figure 4] 1 is a graphical representation of the percent stability of refrigerated aceclidine compositions over a 30 month period at 5 and 25 degrees Celsius. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0075] Detailed Description of the Invention The present invention is directed to compositions and methods for treating presbyopia, irregular astigmatism and / or refractive error comprising administering to a patient in need thereof a pharmaceutical composition comprising a muscarinic agonist that preferentially activates M1 and M3 muscarinic acetylcholine receptors, preferably M1 over M3, most preferably aceclidine or a derivative thereof. It has surprisingly and unexpectedly been discovered that aceclidine provides enhanced presbyopia reversal during the day or at night (wherein viewing involves one or more direct or reflected light sources) with negligible side effects using the compositions of the present invention.
[0076] Aceclidine is traditionally used as a treatment for glaucoma. When aceclidine is used to treat glaucoma, it is usually stored in a two-bottle system; one bottle contains lyophilized aceclidine, and the second bottle contains the diluent required to reconstitute lyophilized aceclidine before topical instillation. Romano JH, Double-blind cross-over comparison of aceclidine and pilocarpine in open-angle glaucoma, Brit J Ophthal, Aug 1970, 54(8), 510-521. It is a further aspect of the present invention to provide an aqueous aceclidine composition that is stable in combination with cold chain storage. It is yet a further aspect of the present invention to provide a method for stabilizing aqueous aceclidine by combining effective excipients, pH ranges and temperature ranges.
[0077] The compositions and methods of the present invention treat presbyopia by improving depth of focus in patients with presbyopia by administering to the eye an ophthalmic composition that reduces pupil dilation in the dark or dim light, produces a particular degree and duration of miosis without accommodation, provides whitening and / or induces anti-reduction. The compositions and methods of the present invention, moreover, do not cause significant pupil rebound, tachyphylaxis, ciliary spasm, induce myopia or reduce distance vision. Furthermore, the compositions and methods of the present invention allow further improvement in visual acuity and depth perception for binocular (both eyes) treatment. The ophthalmic compositions of the present invention surprisingly produce pupils of about 1.5 mm to about 2.4 mm at the anterior iris and about 2.0 mm at the corneal surface. Without wishing to be bound by a particular theory, the clinical effect appears to involve both a modulated increase in accommodative tone and an enhanced pinhole near depth of focus for improved near vision estimated at about -1.25D or less. However, the power is limited to remain within the pinhole correction of hyperopia, found to be approximately -1.00D or less, so that the sum is increased and in some cases, near vision of +2.00D or more may be added without hyperopia blurring. And with the reduction or elimination of redness that is otherwise characteristic of the use of miotic drugs. The pupillary constriction of the present invention with such modulation and limiting of peak accommodative tone is superior to the pinhole effect of Kamra® and Flexivue Microlens® corneal inlays, allowing binocular treatment without peak dimming. The pupillary constriction of the present invention with modulated accommodation is also superior to inlays, because the actual pupillary constriction does not result in the severe night vision impairment caused by the light scattering boundary of the precorneal pinhole created by the inlay. Further pupil constriction provides a wider field of view and more focused light transmission, achieving negligible, mild and very acceptable photochromic and enhanced contrast, distance vision, reduced night glare and improved near vision in the discovered optimal pupil range of approximately 1.5mm to 2.1mm using the prescription findings of the present invention.
[0078] The use of aceclidine reduces the risk of retinal detachment when compared to the use of common muscarinic agonists such as pilocarpine and carbachol, due to minimal impact on the vertical ciliary muscle. The further inclusion of a cycloplegic agent resulted in a shallowing of the anterior chamber by only 0.04 mm. Aceclidine also provides greater control of magnitude, duration, and minimum pupil diameter than conventional pilocarpine, with or without an alpha agonist, and less anterior chamber inflammation with chronic use, especially as enhanced for the present invention. The compositions of the present invention achieve these benefits by allowing both the benefits of pinhole myopic depth perception and a modest accommodative increase below the threshold of myopic distance blur induced through a miotic pupil, thereby, without wishing to be bound by a particular theory, it is believed that in preferred embodiments, the rate of miosis and the rate of accommodative increase maintain a synchronous balance, allowing pinhole correction of accommodative blur otherwise induced in the application of conventional techniques of miosis for presbyopia correction. Thus, this combination has been found to prevent the far-distance blurring and excessive accommodative myopia and ciliary spasms that would normally be seen in patients in response to pilocarpine and / or carbachol induced miosis without the discovery of the formulations of the present invention, as well as the manifestations of headaches or generalized migraine-like headaches.
[0079] Such conventional formulations of pilocarpine to provide a reasonable duration of effect are still limited in most cases to about 4 hours or less because a high ratio of accommodation to pupillary constriction minimizes but does not eliminate distance-induced myopic blur and ciliary spasm, requiring a minimum concentration of about 1.0% pilocarpine. Furthermore, pilocarpine must be instilled monocularly to minimize intolerable distance blur and even more bothersome 2-3 line distance blur. Even when injected monocularly, pilocarpine can still cause bothersome associated distance blur and must be limited to about 1.0%. Instillation of 1.0% pilocarpine results in pupil size of about 2.3 mm or more in most subjects, thereby limiting the important benefits of pinhole depth perception as well as pinhole filtering of induced myopic rays. The limitation of pilocarpine to about 1.0% in these conventional formulations, with its attendant short-term, yet troublesome, reduction in distance blur in emmetropia or myopia (somewhat counteracted in low hyperopia), attempts to prevent the very strong accommodation of 5D to 11D that is well known to occur at higher concentrations of pilocarpine.
[0080] In a preferred embodiment, by combining miotics and cycloplegics in a narrow specific ratio of miosis to cycloplegia, such as that found for U.S. Pat. No. 9,089,562, e.g., about 35:1 for the preferred embodiment, any effect on accommodation can be further reduced or completely eliminated, and in the present invention, in the presence of cryoprotectants, is significantly increased by a factor of about 300% to 700%. Aceclidine can provide an increase in depth of focus with both pupillary constriction of less than 2.3 mm and moderate accommodation as described in the present invention. Particularly enhanced miosis occurs with the use of the compositions of the present invention. This enhanced miosis allows the use of alpha-2 agonists at very low concentrations when needed to relieve mild eye redness. Other combinations of inactive ingredients reduce or effectively eliminate redness induced without such agonists. Moreover, due to the apparent and surprisingly selective nature of aceclidine, and the discovery of the commercially stable aceclidine formulations of the present invention, administration of the compositions of the present invention to the eye results in a net strongly enhanced near vision from both the pupillary pinhole effect and moderately accommodated ciliary accommodation. These beneficial effects are accompanied by a filtering pupil effect that eliminates the far-distance blur from accommodation and often corrects residual refractive errors and optical aberrations that may be present to also improve far-distance vision.
[0081] Certain embodiments of the present invention enhance the favorable degree of pupil constriction found by providing a range of effect of about 1.50-2.20 mm for most patients using preferred embodiments of non-ionic surfactants and viscosity enhancers. Similar benefits can be achieved using other penetration enhancers, particularly Carbopol® (polyacrylic acid or carbomer), as well as various viscosity additives that extend drug residence time, such as xanthan gum, guar gum, alginates and other in situ gels well known to those skilled in the art. It is well known to those skilled in the art that the exact concentration of a particular viscosity agent depends on both the molecular weight and concentration of the agent selected, and an increase in molecular weight can have the same viscosity even if the concentration is decreased. The present invention further prevents nasal congestion that occurs when large aceclidine levels reach the nasal mucosa due to the rheological properties of the preferred embodiments.
[0082] The combination of aceclidine and low concentrations of selective alpha-2 adrenergic receptor agonists (alpha-2 agonists or alpha-2 adrenergic agonists), such as fadolmidine, brimonidine or guanfacine, allows the desired miotic effect with reduced or no hyperemia. The use of low concentrations of selective alpha-2 agonists results in a substantial reduction in hyperemia, with a greatly reduced risk of rebound hyperemia found at concentrations of about 0.06% w / v and above. Furthermore, the use of low concentrations of selective alpha-2 agonists does not adversely alter the pupil constriction caused by aceclidine. In contrast, the use of 0.20% w / v brimonidine, when applied topically to pupil accommodation for night vision, results in tachyphylaxis of pupil accommodation due to upregulation of alpha-2 receptors in nearly 100% of treated subjects within 4 weeks of use.
[0083] Unexpectedly, the addition of a cycloplegic agent results in less pain or associated discomfort at the supraorbital rim by further reducing the degree of cyclospasm with topical instillation without loss of miotic response.More unexpectedly and surprisingly, the ratio of 1.40% aceclidine to about 0.040% tropicamide in the preferred embodiment of U.S. Pat. No. 9,089,562 (35:1) goes from about 1.75% aceclidine to about 0.004%-0.010% tropicamide (350:1 and 175:1, respectively) in the presence of mannitol, with 2.5% providing better efficacy than 4.0%.
[0084] This lack of miotic response deficit is an unexpected and surprising finding, since certain cycloplegic agents, such as tropicamide, have known pupil dilatation effects at concentrations as low as 0.01% w / v (Grunberger J. et al., The pupillary response to differentiation of various types of dementia, Neuropsychiatr, 2009, 23(1), pg57). More specifically, cycloplegic agents cause pupil dilation (i.e., dilation of the radial muscle of the iris). Furthermore, the addition of a cycloplegic agent to a miotic agent unexpectedly increases the time that the pupil remains in the desired size range without becoming too restricted. The peak miotic effect at 30-60 minutes can be titrated inversely to the cycloplegic agent concentration. The concentrations of tropicamide discovered in this invention apparently cause more relaxation of the ciliary muscle than the radial musculature of the iris. In fact, it has been found that iris mydriasis is suppressed by the addition of tropicamide to the composition containing aceclidine at the concentration used in the present invention, and instead, the miosis is at a more consistent level during the duration of the miosis effect.Furthermore, quite surprisingly, unexpectedly, and beneficially, the addition of tropicamide can reduce the degree of peak pupillary constriction without inducing mydriasis, thereby resulting in a more consistent and ideal pupil size throughout drug-induced miosis.This more consistent pupil size allows for beneficial near and far vision without the harmful blurring or loss of resolution due to diffraction limit at the very reduced pupil size (e.g. 1.25mm) seen at peak pupillary constriction.
[0085] Previously, in U.S. Patent No. 9,089,562, it was surprisingly found that the addition of at least 0.04% w / v cycloplegic agent, in preferred embodiments, results in a reduction of the ciliary side effects caused by administration of aceclidine (1.40%) to the eye. However, such formulations are not constructed sufficiently stable for commercial use, typically having a maximum duration of about 5-6 hours.
[0086] Several additional discoveries of the present invention allow for commercially stable aceclidine formulations with enhanced efficacy and duration.
[0087] Equally surprising, or even more surprising, than the synergistic effect of 0.040% cycloplegic added to 1.40% aceclidine is the discovery of the present invention that the combination of 1.50% to 2.0% (preferably about 1.75%) aceclidine with a cryoprotectant, preferably a polyol, in a preferred embodiment, particularly 0.5% to 4.0%, most preferably about 2.5% mannitol, can achieve similar pupil coverage with reduced or no ciliary side effects. The combination of a cryoprotectant with aceclidine then allows for lyophilization without decomposing aceclidine, while at the same time further reducing or eliminating the need for a cycloplegic drug in the present invention, relative to the teaching of the cycloplegic concentration range required in U.S. Pat. No. 9,089,562. Thus, optionally, the addition of a cryoprotectant may be used to further eliminate mild but potentially bothersome ciliary side effects, particularly in young presbyopes, and to significantly reduce the concentration of cycloplegia required to further accommodate pupillary constriction than the combination of aceclidine and cryoprotectant alone (i.e., 0.025% w / v or less, preferably 0.004%-0.015%, most preferably 0.005%-0.010% cycloplegia agent). As seen in preferred embodiments of the present invention, bothersome peak concentration dimming is reduced and in most cases eliminated. In preferred embodiments, it has been discovered that about 1.50%-2.0%, more preferably 1.75%, aceclidine and about 0.5%-4.0%, more preferably 2.5%, mannitol provide the optimal concentration combination for the present invention, but the discovery of additive formulations may further enhance the degree and duration of clinically desired general improvement, where the desired degree of general improvement of about 3 lines and duration of 5 hours or more is necessary but not sufficient for an effective topical presbyopic composition.
[0088] Surprisingly, it has been discovered that while the addition of a viscosity agent to the composition of item a above only results in a slight improvement in size and duration, an optimum concentration has been found that provides the present invention with significantly improved size and duration when a non-ionic surfactant such as polyoxyl stearate or polysorbate 80 is added first, and the viscosity can provide a much greater duration of addition than when added alone. It has been found that concentrations of polysorbate 80 or polyoxyl 40 stearate between 1.0% and 10.0%, more preferably about 2.5% to 5.0% w / v, are beneficial.
[0089] Combining the formulation improvements of a. and b. above results in preferred embodiments such as 1.75% aceclidine, 2.5% mannitol, and 2.75% polysorbate 80. Viscosity agents such as high viscosity carboxymethylcellulose ("CMC") have surprisingly been found to moderately increase magnitude and significantly increase duration, unlike the formulations above alone. Combining high molecular weight CMC concentrations of 0.75% to 1.75%, most preferably about 1.40%, or hydroxypropylmethylcellulose ("HPMC") of about 0.25% to 2.0%, more preferably about 0.50% or 1.50%, most preferably about 1.0% to 1.25%, results in an improvement in near vision of about +3 lines or more, with a duration of 5 to 10 hours, averaging about 7 hours or more, longer than 1.0% pilocarpine, which is less than about 4 hours.
[0090] While not wishing to be bound by any particular theory, citrate in combination with EDTA as a buffer in the preferred embodiment appears to reduce congestion and 2) extend the shelf life of the sorbate preservative, and in combination with BAK, at 0.005% to 0.02% (0.02% preferred), further enhances near vision to about 4 lines and duration to about 8 to 12 hours.
[0091] Additionally, in preferred embodiments, 0.5% or 1.5% sodium chloride is added. Optionally, the sodium chloride may be replaced with boric acid, preferably 0.35%, or potassium borate, preferably 0.47%.
[0092] Without wishing to be bound by any particular theory, the addition of a non-ionic surfactant at an optimized concentration of about 2.5% to 5.0% appears to enhance the penetration of aceclidine into the eye, which may be related to the optimal micelle size, particularly in the micromicelle or nanomicelle range. This increase in penetration coincides with the desired increase in size and duration, with a slight increase in ciliary sensation and photochromic in the absence of tropicamide but in the presence of mannitol. Thus, in the presence of the combination of formulation enhancements a-d above, a cycloplegic agent is no longer necessary in a-d above, and the addition of a non-ionic surfactant at the concentration found to be preferred may be further improved with much lower concentrations of cycloplegic agent than those found in U.S. Pat. No. 9,089,562, such as the use of about 0.042% tropicamide and 1.40% aceclidine. In the present invention, a preferred embodiment includes about 1.75% aceclidine, 2.5% mannitol, about 2.5%-5.0% polysorbate 80, about 1.42% CMC, or about 1.8% HPMC, and about 0.004%-0.010%, more preferably about 0.005% to 0.007%, and most preferably about 0.005%-0.006% tropicamide. Micelle formation above the critical micelle concentration may allow the micelles to spread across the tear film surface and to cover this surface at low concentrations, while at higher concentrations these micelles become increasingly contracted and "squeezed" along the surface.
[0093] Without wishing to be bound by any particular theory, in a preferred composition of 1.75% aceclidine, 2.5% mannitol, 0.01% tropicamide, and citrate buffer (1-100 mM, preferably 3-5 mM), about 0.10% sorbate, about 0.10% EDTA, and 0.02% BAK is above the critical micelle concentration of BAK. BAK, a cationic surfactant, and the resulting ionic micelle gradient with + charge NH4 + quaternary nitrogen, with polar heads condensing outwards and lipophilic alkyl chains inwards on the hydrophobic tail, can cause significant similar aceclidine alignment due to the dipole with the quaternary NH3 nucleophilic or NH4 protonated nitrogen oriented along the outer polar head and the more hydrophobic carbonyl C=O along the hydrophobic BAK micelle tail, which prevents, greatly reduces, or moderately reduces collisions of non-ionic aceclidine molecules (nucleophiles), which, when randomly oriented in solution to collide with another aceclidine carbonyl, results in chemical conversion of that aceclidine via nucleophilic attack at its target carbonyl, recurring from such nucleophiles to other aceclidines so repeatedly oriented, causing loss of stability without BAK orientation, via 0.005%, preferably 0.01%-0.02%, most preferred micelles. Although the concentration of such non-ionic nucleophiles at the preferred pH in the preferred embodiment is relatively low, the ability of these non-ionic nucleophiles to repeatedly destabilize adjacent aceclidines without decomposing themselves is high, which may result in mixing of the lyophilized aceclidine / mannitol with the remaining formulation in the diluent upon opening of the dual chamber bottle, improving the potency of the mixed solution for over a month and / or improving stability sufficient for commercialization in solution at either room temperature or in the cold chain.
[0094] It has been discovered that BAK alone does not provide sufficient bacterial and fungal preservative effect, but BAK and sorbate, or sorbate alone, adequately preserves the diluents and / or mixed solutions of the present invention.
[0095] While not wishing to be bound by any particular theory, preferred embodiments of the present invention, such as those containing 1.25% hydroxypropyl methylcellulose, may have a viscosity of about 400 cps prior to instillation, unlike conventional high viscosity artificial tear formulations such as Celluvisc®, which is about 400 cps. This may blur vision for 10-20 minutes, or Liquigel® at about 100 cps, which may result in a similar but slightly less blurred vision, and about 60 seconds of blurring that dissipates rapidly with the influx of tear secretion. This may be due to both the reduction in non-Newtonian viscosity at high shear (such as about 1 / 1000th of a second during blinking) and the parasympathetic triggering of tear secretion as a sialogens.
[0096] Common miotic drugs such as pilocarpine, carbachol, and phosphodiesterase can cause pupil constriction and improve near vision in presbyopic patients. However, the distance vision associated with these common miotic drugs is adversely reduced from the peak effect and miosis during accommodation that is not seen with aceclidine. Coadministration of cycloplegic drugs with aceclidine surprisingly results in attenuating this decrease in distance vision.
[0097] The comfort, safety, and effectiveness of preferred embodiments of the ophthalmic compositions of the present invention are due to the presence of cyclodextrin alpha, beta, or gamma chains, preferably 2-hydroxypropyl beta-cyclodextrin ("HPβCD"), and sulfobutyl ether derivatives of beta cyclodextrin (Captisol®), polyoxyl alkyls such as polyoxyl 40 stearate and polyoxyl 35 castor oil, or poloxamers such as Poloxamer 108 and Poloxamer 407, polysorbates such as polysorbate 80 or Brij® 35 (Brij® is a registered trademark of Uniqema Americas LLC); viscosity agents such as carboxymethylcellulose ("CMC"); tonicity modifiers such as sodium chloride; preservatives such as benzalkonium chloride; and a pH of about 5.0 to about 8.0. Additionally, increased concentrations of nonionic surfactants may result in reduced redness. Specifically, increasing polysorbate from 0.10% to 0.50-1.0% reduces hyperemia, and increasing CMC or Carbopol® 940 to 0.50-1.5% w / v (preferably 1.40-1.43% w / v) improves near vision both quantitatively and over time.
[0098] The viscosity of the compositions of the invention including the viscosity agent can be from about 1 to about 10,000 cps prior to topical instillation in the eye. As a result of the shear forces applied to the composition as it exits the device used for administration, the viscosity decreases to a range of about 1 to about 25 cps at the high shear of a blink and to a range of 50 cps to 200 cps at the low shear between blinks. This allows for greater drop retention with reduced spillage, nasolacrimal drainage and systemic absorption upon topical instillation.
[0099] definition As used herein, the term "composition" is intended to encompass a product comprising the specified ingredients in the specified amounts, and a product that results directly or indirectly from combining the specified ingredients in the specified amounts.
[0100] The term "stabilization" as used herein refers to any process that facilitates and / or allows an active agent to remain in solution. The term "stabilization" as used herein also refers to any means or process that inhibits and / or reduces the tendency of muscarinic agonists, including aceclidine, to decompose.
[0101] As used herein, all numerical values relating to amounts, weights, and the like defined as "about" each particular value are plus or minus 10%. For example, the phrase "about 5% w / v" should be understood as "4.5% w / v to 5.5% w / v." Thus, amounts within 10% of the claimed value are encompassed by the scope of the claims.
[0102] As used herein, "% w / v" refers to the percentage by weight of the total composition.
[0103] As used herein, the term "subject" refers to, but is not limited to, a human or other animal.
[0104] As used herein, the term "container" refers to a pharma- ceutically acceptable container that includes a chamber suitable for containing a liquid drug product. Containers include, for example, vials, syringes, capsules, and ampoules.
[0105] As used herein, "headspace" refers to the area within the chamber of a container between the composition and the cap when the cap is oriented away from gravity.
[0106] As used herein, the term "cap" or "closure" refers to any article capable of preventing a composition from exiting a container.
[0107] The term muscarinic receptor agonist ("muscarinic agonist") includes agonists that activate muscarinic acetylcholine receptors ("muscarinic receptors"). Muscarinic receptors are divided into five subtypes, designated M1-M5. Muscarinic agonists of the present invention include those muscarinic agonists that preferentially activate M1 and M3 receptors over M2, M4 and M5 receptors ("M1 / M3 agonists"). M1 / M3 agonists include, but are not limited to, aceclidine, xanomeline, talsaclidine, sabcomeline, cevimeline, albamerin, arecoline, miramelin, SDZ-210-086, YM-796, RS-86, CDD-0102A (5-[3-ethyl-1,2,4-oxadiazol-5-yl]-1,4,5,6-tetrahydropyrimidine hydrochloride), N-aryl urea substituted 3-morpholine arecoline, VUO255-035 (N-[3-oxo-3-[4-(4-pyridinyl)-1-piperazinyl]propyl]-2,1,3-benzothiadiazine quiniclidinone rings with one or more carbon substitutions, including esters, sulfur, or 5 or 6 carbon ring structures, including substituted nitrogens and / or oxygens, or pharma- ceutically acceptable salts, esters, analogs, prodrugs, or derivatives thereof. A preferred M1 / M3 agonist is aceclidine. In a preferred embodiment, the muscarinic agonists of the present invention include those muscarinic agonists that preferentially activate M1 and M3 over M2, M4, and M5; more preferably, activate M1 over M3. In a more preferred embodiment, the muscarinic agonists of the present invention include those muscarinic agonists that activate only M1.
[0108] The term "aceclidine" includes, but is not limited to, aceclidine as a racemic mixture, the aceclidine (+) enantiomer, the aceclidine (-) enantiomer, aceclidine analogues including, but not limited to, highly M1 selective 1,2,5 thiadiazole substituted analogues such as those disclosed in Ward. JS et al., 1,2,5-Thiadiazole analogues of faceclidine aspotent m1 muscarinic agonists, J Med Chem, 1998, Jan. 29, 41(3), 379-392, and salts, esters, analogues, prodrugs and derivatives thereof, including, but not limited to, aceclidine prodrugs including carbamate esters.
[0109] The term "selective alpha-2 adrenergic receptor agonist" or "alpha-2 agonist" includes all alpha-2 adrenergic receptor agonists that have a binding affinity of 900 times or more for alpha-2 over alpha-1 adrenergic receptors, or 300 times or more for alpha-2a or alpha-2b over alpha-1 adrenergic receptors. The term also includes pharma- ceutically acceptable salts, esters, prodrugs, and other derivatives of selective alpha-2 adrenergic receptor agonists.
[0110] The term "inert gas" refers to a gas that is chemically inert and does not react with other compounds. Inert gases include, but are not limited to, helium, neon, argon, krypton, xenon, radon, and nitrogen.
[0111] The term "low concentration" or "low dose" of an alpha 2 adrenergic receptor agonist refers to a concentration of about 0.0001% to about 0.065% w / v, more preferably, about 0.001% to about 0.035% w / v; even more preferably, about 0.01% to about 0.035% w / v; even more preferably, about 0.03% to about 0.035% w / v.
[0112] The term "brimonidine" includes, without limitation, brimonidine salts and other derivatives, including, but not limited to, brimonidine tartrate, 5-bromo-6-(2-imidazolin-2-ylamino)quinoxaline D-tartrate, and Alphagan®.
[0113] The terms "treating" and "treatment" refer to reversing, alleviating, inhibiting or slowing the progression of a disease, disorder or condition to which such term applies, or one or more symptoms of such disease, disorder or condition.
[0114] The term "pharmacologically acceptable" describes a material that is not biologically or otherwise undesirable (i.e., does not cause unacceptable levels of undesirable biological effects or interact in a deleterious manner).
[0115] As used herein, the term "pharmaceutical effective amount" refers to an amount sufficient to achieve a desired biological effect, such as a beneficial outcome, including, without limitation, prevention, reduction, amelioration, or elimination of signs or symptoms of a disease or disorder. Thus, the total amount or method of each active component of a pharmaceutical composition is sufficient to show a meaningful target benefit. Thus, the "pharmaceutical effective amount" will depend on the context in which it is administered. A pharmaceutical effective amount may be administered in one or more prophylactic or therapeutic administrations.
[0116] The term "prodrug" refers to compounds, including but not limited to, monomers and dimers of the compounds of the present invention that have cleavable groups and that, under physiological conditions, become compounds that are pharma- ceutical active in vivo.
[0117] As used herein, "salt" refers to salts that retain the biological effectiveness and properties of the parent compound and that are not biologically or otherwise harmful at the dosages administered. Salts of the compounds of the present invention can be prepared from inorganic or organic acids or bases.
[0118] The term "high order aberrations" refers to aberrations in the visual field selected from starburst, halo (spherical aberration), diplopia, multiple images, smeared vision, coma, and trefoil aberrations.
[0119] The term "cold chain" refers to storage at a temperature of about 2 to about 8°C from the time of manufacture until just before administration.
[0120] The compound of the present invention can be used in the form of pharmaceutically acceptable salts derived from inorganic or organic acids or bases.The phrase "pharmaceutically acceptable salts" refers to salts that are suitable for use in contact with human and lower animal tissues without excessive toxicity, irritation, allergic reactions, etc., within the scope of sound medical judgment, and are commensurate with a reasonable benefit / risk ratio.Pharmaceutically acceptable salts are well known in the art.For example, SM Berge et al. describe pharmaceutically acceptable salts in detail in J.Pharmaceutical Sciences, 1977, 66:1 et seq.
[0121] The salts can be prepared in situ during the final isolation and purification of the compounds of the invention, or separately by reacting the free base function with a suitable organic acid. Representative acid addition salts include, but are not limited to, acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate (isothionate), lactate, maleate, methanesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, palmitate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, phosphate, glutamate, bicarbonate, p-toluenesulfonate, and undecanoate. Basic nitrogen-containing groups can also be quaternized with agents such as lower alkyl halides, such as methyl, ethyl, propyl and butyl chlorides, bromides and iodides; dialkyl sulfates, such as dimethyl, diethyl, dibutyl and diamyl sulfate; long chain halides, such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides; aryl alkyl halides, such as benzyl and phenethyl bromides and others. Water or oil-soluble or dispersible products are thereby obtained. Examples of acids that can be used to form pharmaceutically acceptable acid addition salts include inorganic acids, such as hydrochloric acid, hydrobromic acid, hyaluronic acid, malic acid, sulfuric acid and phosphoric acid, and organic acids, such as oxalic acid, malic acid, maleic acid, methanosulfonic acid, succinic acid and citric acid.
[0122] Base addition salts can be prepared in situ during the final isolation and purification of the compounds of the present invention by reacting a carboxylic acid-containing moiety with a suitable base, such as a hydroxide, carbonate, or bicarbonate of a pharma-ceutically acceptable metal cation, or with ammonia or an organic primary, secondary, or tertiary amine. Pharmaceutically acceptable salts include cations based on alkali metals or alkaline earth metals, such as, but not limited to, lithium, sodium, potassium, calcium, magnesium, and aluminum salts, as well as non-toxic quaternary ammonia and amine cations, including ammonium, tetramethylammonium, tetraethylammonium, methylammonium, dimethylammonium, trimethylammonium, triethylammonium, diethylammonium, and especially ethylammonium. Other representative organic amines useful for the formation of base addition salts include ethylenediamine, ethanolamine, diethanolamine, piperidine, piperazine, and the like.
[0123] The term "ester" as used herein refers to an ester of the formula -OC(O)A 1 or -C(O)OA 1 In the formula, A 1 may be an alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl, heteroaryl group or other suitable substituent.
[0124] Compositions of the Invention In one embodiment, the present invention relates to an ophthalmic composition comprising aceclidine. In a preferred embodiment, aceclidine is at a concentration of about 0.25% w / v to about 2.0% w / v, more preferably about 0.50% w / v to about 1.90% w / v, even more preferably about 1.65% w / v to about 1.85% w / v, and most preferably about 1.75% w / v. Since aceclidine is a tertiary amine with asymmetry, both + and - optical isomers exist (in some studies it is believed that the (+) is more potent, while in others the (-) may be more potent). For the above concentrations, polarimetry has demonstrated exactly equal ratios of (+) and (-) isomers for these concentrations. Thus, changing this ratio may alter this concentration range in proportion to the change in ratio.
[0125] The present invention further relates to an ophthalmic composition comprising a muscarinic agonist, preferably a non-ionic surfactant above its critical micelle concentration for the composition, and a viscosity agent; or alternatively an in situ gelling agent. In a preferred embodiment, the initial viscosity of the composition upon topical application is greater than 20 cps at low shear (1 / s), preferably greater than 50 cps, more preferably greater than 70 cps.
[0126] A cryoprotectant is a compound that prevents freezing or damage to a compound during freezing. As used herein, the term "cryoprotectant" or "cryoprotectants" includes cryoprotectants. Cryoprotectants suitable for use in the present invention include, but are not limited to, polyols, sugars, alcohols, lower alkanols, lipophilic solvents, hydrophilic solvents, bulking agents, solubilizers, surfactants, antioxidants, cyclodextrins, maltodextrins, colloidal silicon dioxide, polyvinyl alcohol, glycine, 2-methyl-2,4-pentanediol, cellobiose, gelatin, polyethylene glycol (PEG), dimethyl sulfoxide (DMSO), formamide, antifreeze protein 752, or combinations thereof.
[0127] As used herein, the term "polyol" refers to a compound having multiple hydroxyl functional groups available for organic reaction, such as monomeric polyols, such as glycerin, pentaerythritol, ethylene glycol, and sucrose. Additionally, polyol may refer to polymeric polyols, including glycerin, pentaerythritol, ethylene glycol, and sucrose reacted with propylene oxide or ethylene oxide. In a preferred embodiment, the polyol is selected from the group consisting of mannitol, glycerol, erythritol, lactitol, xylitol, sorbitol, isosorbide, ethylene glycol, propylene glycol, maltitol, threitol, arabitol, and ribitol. In a more preferred embodiment, the polyol is mannitol.
[0128] Sugars suitable for use in the present invention as cryoprotectants include, but are not limited to, glucose, sucrose, trehalose, lactose, maltose, fructose, and dextran.
[0129] In another preferred embodiment, the alcohol includes, but is not limited to, methanol.
[0130] In one embodiment, the present invention excludes each cryoprotectant individually from the definition of cryoprotectant.
[0131] Cryoprotectants may currently be present in the compositions of the present invention at a concentration of from about 0.1% to about 99% w / v, preferably from about 1% to about 50% w / v, and more preferably from about 1% to about 10% w / v.
[0132] Lower alkanols suitable for use in the present invention include, but are not limited to, amyl alcohol, butanol, sec-butanol, t-butyl alcohol, n-butyl alcohol, ethanol, isobutanol, methanol, isopropanol, and propanol.
[0133] Bulking agents suitable for use in the present invention include, but are not limited to, sugars, polyvinylpyrrolidone, cyclodextrin, and trehalose.
[0134] Solubilizing agents suitable for use in the present invention include, but are not limited to, cyclic amides, gentisic acid, and cyclodextrins.
[0135] In a preferred embodiment, surfactants suitable for use in the present invention include, but are not limited to, non-ionic surfactants, more preferably surfactants having a hydrophilic-lipophilic balance ("HLB") value of 1-18.
[0136] In a preferred embodiment, antioxidants suitable for use in the present invention include, but are not limited to, bisulfites, ascorbic acid, disodium ethylenediaminetetraacetate or tetrasodium ethylenediaminetetraacetate, citrates, butylated hydroxyanisole ("BHA"), butylated hydroxytoluene ("BHT"), sulfoxylates, propyl gallate, amino acids containing a thio group, and thiols.
[0137] Nonionic surfactants suitable for the present invention include cyclodextrins, polyoxyl alkyls, poloxamers, or combinations thereof, and may further include combinations with other nonionic surfactants such as polysorbates. Preferred embodiments include polyoxyl 40 stearate and optionally poloxamer 108, poloxamer 188, poloxamer 407, polysorbate 20, polysorbate 80, ionically charged (e.g., anionic) cyclodextrins with or without beta-butyric acid (Captisol®), 2-hydroxypropyl beta cyclodextrin ("HPβCD"), alpha cyclodextrin, gamma cyclodextrin, polyoxyl 35 castor oil, and polyoxyl 40 hydrogenated castor oil, or combinations thereof. Additionally, substitution of other non-ionic surfactants compatible with ophthalmic use allows for similar formulation benefits, including, but not limited to, poloxamer, poloxamer 103, poloxamer 123, and poloxamer 124, poloxamer 407, poloxamer 188, and poloxamer 338, any poloxamer analog or derivative, polysorbate, polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, any polysorbate analog or derivative, cyclodextrin, hydroxypropyl-β-cyclodextrin, hydroxypropyl-γ-cyclodextrin, randomly methylated β-cyclodextrin, β-cyclodextrin sulfo. butyl ether, gamma-cyclodextrin sulfobutyl ether or glucosyl-beta-cyclodextrin, any cyclodextrin analog or derivative, polyoxyethylene, polyoxypropylene glycol, polysorbate analog or derivative, polyoxyethylene hydrogenated castor oil 60, polyoxyethylene (200), polyoxypropylene glycol (70), polyoxyethylene hydrogenated castor oil, polyoxyethylene hydrogenated castor oil 60, polyoxyl, polyoxyl stearate, nonoxynol, octylphenol ethoxylate, nonylphenol ethoxylate, capryol, lauroglycol, polyethylene glycol ("PEG"), Brij® 35, 78, 98,700 (polyoxyethylene glycol alkyl ether), glyceryl laurate, lauryl glucoside, decyl glucoside, or cetyl alcohol; or zwitterionic surfactants such as palmitoyl carnitine, cocamide DEA, cocamide DEA derivatives cocamidopropyl betaine, or trimethylglycine betaine, N-2(2-acetamido)-2-aminoethanesulfonic acid (ACES), N-2-acetamidoiminodiacetic acid (ADA), N,N-bis(2-hydro N,N-bis(2-hydroxyethyl)-3-amino-2-hydroxypropanesulfonic acid (DIPSO), 4-(2-hydroxyethyl)-1-pyridylaminoethanesulfonic acid (BES), 2-[bis-(2-hydroxyethyl)-amino]-2-hydroxymethyl-propane-1,3-diol (bis-tris), 3-cyclohexylamino-1-propanesulfonic acid (CAPS), 2-cyclohexylamino-1-ethanesulfonic acid (CHES), ...4-(2-hydroxyethyl)-1-pyridylaminoethanesulfonic acid (BES), 4-(2-hydroxyethyl)-1-pyridylaminoethanesulfonic acid (BES), 4-(2-hydroxyethyl)-1-pyridylaminoethanesulfonic acid (BES), 4-(2-hydroxyethyl)-1-pyridylaminoethanesulfonic acid (BES), 4-(2-hydroxyethyl)-1-pyridylaminoethanesulfonic acid (BES), 4-(2-hydroxyethyl)-1-pyridylaminoethanesulfonic acid (BES), 4-(2-hydroxyethyl)-1-pyridylaminoethanesulfonic acid (BES), 4-(2-hydroxyethyl)-1-pyridylaminoethanesulfonic acid Perazinepropanesulfonic acid (EPPS), N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (HEPES), 2-(N-morpholino)-ethanesulfonic acid (MES), 4-(N-morpholino)-butanesulfonic acid (MOBS), 2-(N-morpholino)-propanesulfonic acid (MOPS), 3-morpholino-2-hydroxypropanesulfonic acid (MOPSO), 1,4-piperazine-bis-(ethanesulfonic acid) (PIPES), piperazine-N, N'-Bis(2-hydroxypropanesulfonic acid) (POPSO), N-tris(hydroxymethyl)methyl-2-aminopropanesulfonic acid (TAPS), N-[tris(hydroxymethyl)methyl]-3-amino-2-hydroxypropanesulfonic acid (TAPSO), N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid (TES), 2-amino-2-hydroxymethyl-propane-1,3-diol (Tris), Tyloxapol, Solulan, TMOne or more of the nonionic surfactants may be included, such as C-24 (2-[[10,13-dimethyl-17-(6-methylheptan-2-yl)-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]ethanol), and Solulan® 20-80 (sorbitan monolaurate, sorbitan monopalmitate, sorbitan monostearate, and sorbitan monooleate). In certain embodiments, the addition of an anionic surfactant, such as sodium lauryl sulfate and / or sodium lauryl sulfate ester, may be preferred. In other embodiments, the addition of polysorbate 80 is preferred. In addition to the above nonionic surfactants, any nonionic surfactant is suitable for use in the present invention, so long as the concentration of the nonionic surfactant is such that it exceeds the critical micelle concentration of the nonionic surfactant. Preferably, the non-ionic surfactants used in the present invention achieve submicron diameter micelles, more preferably diameters less than 200 nanometers, more preferably less than 150 nanometers.
[0138] Ophthalmic in situ gels that may be added in place of or in addition to one or more non-ionic surfactants include, but are not limited to, gelatin, carbopols of various molecular weights including carbomer 934P and 974P, xanthan gum, alginic acid (alginates), guar gum, locust bean gum, chitosan, pectin and other gelling agents well known to those skilled in the art.
[0139] In a preferred embodiment, the non-ionic surfactant is polyoxyl 40 stearate at a concentration of about 1 to about 15% w / v, more preferably about 5.5% w / v.
[0140] In such preferred embodiments, polyoxyl 40 stearate is found to preferentially enhance hypotensive effects over aqueous solutions and other non-ionic surfactants such as poloxamer 407 and β-cyclodextrin, especially in the presence of alpha-2 agonists.
[0141] In other preferred embodiments, the non-ionic surfactant is polysorbate 80 at a concentration of about 0.5% to about 10% w / v, more preferably about 1% to about 7% w / v, and even more preferably about 2% to about 5% w / v, still even more preferably about 2.5% to about 4% w / v, and most preferably about 2.5% or 2.75% or 3% or 4% or 5% w / v.
[0142] Viscosity agents suitable for the present invention include, but are not limited to, guar gum, hydroxypropyl guar ("hp guar"), xanthan gum, alginate, chitosan, Gelrite, hyaluronic acid, dextran, Carbopol® (polyacrylic acid or carbomer), including the Carbopol® 900 series, including Carbopol® 940 (Carbomer 940), Carbopol® 910 (Carbomer 910), and Carbopol® 934 (Carbomer 934), cellulose derivatives such as carboxymethylcellulose ("CMC"), methylcellulose, methylcellulose 4000, hydroxymethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxypropylmethylcellulose 2906, carboxypropylmethylcellulose, hydroxypropylethylcellulose, and hydroxyethylcellulose, polyethylene glycol, polyvinyl alcohol, polyvinylpyrrolidone, gellan, carrageenan, acrylic acid, carboxyvinyl polymers, or combinations thereof.
[0143] In a preferred embodiment, the viscosity agent will have an equilibrium viscosity of less than 100 cps, preferably about 15 to about 35 cps, most preferably about 30 cps. In a preferred embodiment, the viscosity agent is Carbopol® 940 (Carbomer 940) at a concentration of about 0.05% to about 1.5% w / v, preferably about 0.09% to about 1.0% w / v, more preferably 0.09%, 0.25%, 0.5%, 0.75%, 0.9% or 1.0% w / v. In such circumstances, particularly in the case of polyoxyls, in a preferred embodiment, polyoxyl 40 stearate, and cellulose derivatives, particularly hydroxypropyl methylcellulose, the use of non-polysaccharide derivatives for viscosity enhancement, such as polyacrylic acid derivatives (in a preferred embodiment, carbomer, carbomer 934 or 940), may prevent such separation. Alternatively, the use of non-polyoxyl non-ionic surfactants such as polysorbate 80 with either cellulosic or non-cellulosic viscosity agents may be substituted.
[0144] In another preferred embodiment, the viscosity agent is carboxymethylcellulose at a concentration of about 1% to about 2% w / v, more preferably 1.35% to about 1.45% w / v, and most preferably 1.42% w / v or 1.40% w / v.
[0145] In another preferred embodiment, the viscosity agent is hydroxypropyl methylcellulose at a concentration of about 0.5% to about 1.75%, more preferably about 0.75% or 1.5%, even more preferably about 1.0% to about 1.5%, and most preferably about 1.25%.
[0146] Without wishing to be bound by any particular theory, it appears that the quinuclidine nucleus of the heterocyclic nitrogen on aceclidine is so electron rich that it readily attacks not only itself but also surrounding compounds.
[0147] It is a discovery of the present invention that in addition to the preferred embodiment, several modifications may be used alone or in combination to enhance preservation of cold chain stability, including one or more of aceclidine at 1.40% to 1.75%, tropicamide at 0.025% to 0.10%, and optionally, preferably 5.5%, 0.5% to 10% non-ionic surfactants such as polyoxyl 40 stearate (see Table 1).
[0148] The acidic pH is preferably less than 5.5, preferably less than 5.0, and most preferably a pH of about 4.75.
[0149] The viscosity agent preferably has a viscosity at 25° C. of about 15-50 cps, more preferably 20-45 cps, where a preferred embodiment is 0.09%-1.5% Carbomer 940.
[0150] The cryoprotectant addition, in a preferred embodiment, is a polyol, preferably 2.5% to 4.0% mannitol.
[0151] The buffer is added in an amount of 3 to 5 mmol, preferably 2 to 100 mmol, when acetate or phosphate buffer is preferred; and
[0152] The preservative addition is preferably 0.015% BAK.
[0153] A selective alpha-2 agonist may be incorporated into the composition of the invention, or may be applied topically, preferably just a few minutes before, or less preferably just a few minutes after, if an additional measure to reduce nasal congestion or congestion is desired for sensitive subjects. A selective alpha-2 agonist suitable for the invention has minimal alpha-1 agonist activity at low concentrations. For example, for brimonidine or fadolmidine, 1%-2% w / v is considered very high, and 0.5%-1.0% w / v is highly alpha-1 receptor-inducing and toxic for the purposes of the invention. Furthermore, 0.10%-0.5% w / v is too high, and 0.070%-0.10% w / v is associated with a higher than desirable incidence of rebound congestion (although in the case of dexmedetomidine, its high lipophilicity and intraocular penetration reduces the risk of rebound in this range). Although only 0.065% w / v or less is potentially tolerable, 0.050% w / v or even more preferably 0.035% w / v or less is desirable for many alpha-2 agonists depending on their selectivity. On the other hand, some useful activity may occur at further decreases in concentration of one or more orders of magnitude. Brimonidine, fadolmidine and guanfacine of the preferred embodiments of the present invention preferentially stimulate alpha-2 adrenergic receptors, and even more preferably alpha-2b adrenergic receptors, such that alpha-1 adrenergic receptors are not stimulated sufficiently to cause excessive large vessel arteriolar narrowing and vasoconstrictive ischemia. In addition, it has been found that preventing or suppressing congestion in the case of drugs that would otherwise directly cause congestion, such as the acetylcholine agonist, aceclidine, increases compliance in sensitive subjects who may otherwise be susceptible to the use of the formulations of the present invention that do not contain alpha-2 agonists, inducing congestion or nasal congestion. However, since the alpha-2 agonist shifts its ionization equilibrium, the acidic pH is somewhat offset by the fact that the agonist is more effective at neutral or alkaline pH. Thus, each alpha-2 agonist has a preferred pH range depending on its pKa value and lipophilicity when added to the inventive composition containing aceclidine. In the present invention, a pH range of 5.0 to 8.0 is acceptable, but the preferred embodiment is a pH of 5.5 to 7.5, more preferably 6.5 to 7.0.Furthermore, it has been discovered that cyclodextrin and / or polyoxyl 40 stearate as a nonionic surfactant component or as the sole nonionic surfactant results in a higher whitening effect when an alpha-2 agonist is included in the composition rather than poloxamer 407. Although an alpha-2 agonist is not necessary except in occasional sensitive subjects, an alpha-2 agonist may be applied, optionally separately or in certain preferred embodiments, together with formulations of the invention that do not include an alpha-2 agonist, for example formulations having 5.5% w / v polyoxyl 40 stearate as a nonionic surfactant. Fadolmidine represents the alpha-2 agonist with the highest hydrophilicity and therefore, in the present case, high surface retention. Guanfacine is also highly selective and hydrophilic. Brimonidine is highly selective and has moderate lipophilicity. Finally, dexmedetomidine is highly selective, has high lipophilicity, and may be used with low efficacy to reduce hyperemia for the purposes of the present invention (although it may cause fatigue as a side effect in some patients). In a preferred embodiment, 5.5% w / v polyoxyl 40 stearate, 0.80% w / v CMC, 0.037% w / v NaCl, 0.015% w / v EDTA, 5 mM borate buffer, and 0.007% w / v BAK produces hyperemia of about 1.0 to 1.5 out of 4, which lasts transiently for about 10 minutes and returns to near baseline by 30 minutes.
[0154] In one embodiment, the selective alpha-2 adrenergic receptor agonist is a compound having a binding affinity of about 900 or greater, even more preferably about 1000-fold or greater, and most preferably about 1500 or greater.
[0155] The selective alpha-2 adrenergic receptor agonist may be present at a concentration of about 0.0001% to about 0.065% w / v, more preferably about 0.001% to about 0.035% w / v, even more preferably about 0.01% to about 0.035% w / v, and even more preferably about 0.020% to about 0.035% w / v.
[0156] In one embodiment, the selective alpha-2 adrenergic receptor agonist is selected from the group consisting of brimonidine, guanfacine, fadolmidine, dexmedetomidine, (+)-(S)-4-[1-(2,3-dimethyl-phenyl)-ethyl]-1,3-dihydro-imidazole-2-thione, 1-[(imidazolidin-2-yl)imino]indazole, and mixtures of these compounds. Analogs of these compounds that function as highly selective alpha-2 agonists may also be used in the compositions and methods of the invention.
[0157] In a more preferred embodiment, the selective alpha-2 agonist is selected from the group consisting of fadolmidine, guanfacine and brimonidine. In an even more preferred embodiment, the selective alpha-2 agonist is brimonidine in the form of a salt at a concentration of 0.025% to 0.065% w / v, more preferably 0.03% to 0.035% w / v. In a preferred embodiment, the salt is the tartrate salt.
[0158] In another even more preferred embodiment, the selective alpha-2 agonist is fadolmidine in the form of its hydrochloric acid ("HCl") salt at a concentration of about 0.005% to about 0.05% w / v, more preferably, 0.02% to about 0.035% w / v.
[0159] In another even more preferred embodiment, the selective alpha-2 agonist is guanfacine in the form of its HCl salt at a concentration of about 0.005% to about 0.05% w / v, more preferably 0.02% to about 0.035% w / v.
[0160] In another even more preferred embodiment, the selective alpha-2 agonist is dexmedetomidine in the form of an HCl salt at a concentration of about 0.005% to about 0.05% w / v, more preferably 0.04% to about 0.05% w / v.
[0161] In another preferred embodiment, a pH lower than physiological pH has been found to enhance the whitening effect of brimonidine, preferably pH 4.5 to 6.5, more preferably pH 5.5 to 6.0. However, reduction of hyperemia is achieved at all pHs, and enhancement of aceclidine absorption occurs at alkaline pHs, with more effect from certain concentrations, so that a pH range of 4.5 to 8.0 is effective, but a pH range of 6.5 to 7.5 is preferred in the present invention, with 7.0 to 7.5 being most preferred.
[0162] The present invention further relates to ophthalmic compositions further comprising a cycloplegic agent. A surprising and entirely unexpected discovery of the present invention is that certain cycloplegic agents, particularly in the present case, can be combined with miotic agents without reducing the onset, magnitude, or duration of miosis, and further blunt the normally associated spike in miotic effect that coincides with the time of peak absorption in aqueous formulations, providing consistent miosis for times after onset from 15-30 minutes to 6-10 hours, depending on the desired formulation. The addition of a cycloplegic agent also reduces residual discomfort that may occur immediately after topical instillation, possibly as a result of ciliary body spasm or excessive pupillary miosis.
[0163] Cycloplegic agents suitable for the present invention include, but are not limited to, atropine, Cyclogyl® (cyclopentolate hydrochloride), hyoscine, pirenzepine, tropicamide, atropine, 4-diphenylacetoxy-N-methylpiperidine methobromide (4-DAMP), AF-DX384, methoctramine, tripitramine, darifenacin, solifenacin (Vesicare), tolterodine, oxybutynin, ipratropium, oxitropium, tiotropium (Spriva), and otenzepad (also known as AF-DX116 or 11-{[2-(diethylamino)methyl]-1-piperidinyl}acetyl]-5,11-dihydro-6H-pyrido[2,3b][1,4]benzodiazepin-6-one). In a preferred embodiment, the cycloplegic agent is tropicamide at a concentration of about 0.004% to about 0.025% w / v. More preferably, it is about 0.005% to about 0.015% w / v, and even more preferably, it is about 0.005% to about 0.011% w / v, about 0.005% to about 0.007% w / v, and about 0.005% to about 0.006% w / v. In another preferred embodiment, the cycloplegic agent is tropicamide at a concentration of about 0.04% to about 0.07% w / v, or a mixture of pirenzepine or otenzepad at a concentration of about 0.002% to about 0.05% w / v.
[0164] In a preferred embodiment, 0.01% w / v tropicamide was found to slightly reduce supraorbital rim pain, 0.030% w / v further reduced supraorbital rim pain, and 0.04% w / v to about 0.07% w / v completely eliminated supraorbital rim pain, with no reduction in mean pupillary constriction diameter over the duration of effect. Tropicamide in a preferred embodiment demonstrates a completely unexpected sensitivity of effect, where it unexpectedly and very effectively reduced or eliminated supraorbital rim pain and cyclospasm pain at about 0.04% w / v, very significantly further reduced at 0.042% w / v, and (surprisingly, due to its common use as a pupil dilator) absent in a preferred embodiment at 0.044% w / v, with no cycloplegia. Note that tropicamide did not reduce the mean degree of pupillary constriction, the time of onset of pupillary constriction, or subsequent visual benefit. Instead, tropicamide produces a smooth and consistent miotic effect over time by blunting the peak miosis seen in aqueous formulations. It allows the adjustment of peak pupillary constriction to achieve greater effect over time without dilation as found in its conventional use. Specifically, tropicamide is useful in some embodiments to prevent the transient constriction of less than 1.50 mm at 30 to 60 minutes following aceclidine, as well as to reduce the transient excessive and undesirable blurring of vision that may otherwise occur at peak onset of about 30 minutes. As an example, an ophthalmic composition containing 1.53% w / v aceclidine, 5% w / v HPβCD, 0.75% w / v CMC, 0.25% w / v NaCl, 0.01% w / v BAK, and phosphate buffer, pH 7.0; or 1.45% w / v aceclidine; 5.5% w / v polyoxyl 40 stearate; 0.80% w / v CMC; 0.037% w / v NaCl; 0.015% w / v EDTA; 0.007% w / v BAK, and 5 mM phosphate buffer, pH 7.0, was changed from 0.040% w / v tropicamide, which caused moderate haze, to 0.044% w / v tropicamide, which caused nearly undetectable haze in all but the most dim light conditions.This additional pupil size adjustment with the cycloplegic agent allows for sufficient aceclidine concentration for the prolongation effect while blunting the undesirable concomitant peak overconstriction as well as the uncomfortable pain at the supraorbital rim. Surprisingly, and due to its short acting nature, tropicamide achieves this blunting effect without causing mydriasis. Moreover, in preferred embodiments, tropicamide at 0.014% w / v reduces supraorbital rim pain, at 0.021% w / v, it is further reduced, and at 0.028% w / v to 0.060% w / v, and in some embodiments, up to 0.09% w / v, it has been found to completely eliminate supraorbital rim pain without cycloplegia (i.e., paralysis of the ciliary muscles of the eye).
[0165] It has been found that in the case of a racemic 50:50 mixture of (+) and (-) aceclidine enantiomers (some studies suggest that (+) is more potent, others that (-) is more potent), the tropicamide effect can vary depending on the ratio of aceclidine to tropicamide. For example, in an ophthalmic composition of the present invention comprising 1.55% w / v aceclidine, 5.5% w / v HPβCD, or, in a preferred embodiment, polyoxyl 40 stearate, 0.75% w / v CMC (1%=2,500 centipoise), 0.25% w / v NaCl, and 0.01% w / v BAK at pH 7.5, 0.042% w / v tropicamide can be distinguished from 0.035% w / v, the former exhibiting normal indoor night vision and the latter exhibiting slight blurring that is more pronounced at lower concentrations. At higher concentrations, such as about 0.075% to about 0.090% w / v tropicamide, loss of pupil constriction begins in the preferred range of 1.50 mm to 1.80 mm, and obvious mydriasis begins to occur at higher concentrations. Since the isomer ratio changes the effective concentration, this must be a factor in the clinical effect expected with aceclidine. For the preferred embodiment of the present invention, a polarimeter (personal communication Toronto Research Chemicals) was used to determine the exact 50:50 isomer ratio.
[0166] Figure 1 shows the effect of miotics with and without cycloplegic agents and with and without vehicle. Subjects were emmetropic individuals aged 45 years or older with baseline near visual acuity of 20.100 and distance visual acuity of 20.20. Topical application of 1% w / v pilocarpine in saline to the eye improves near visual acuity to 20.40 (8a), but this improvement occurs at the expense of a decrease in distance visual acuity to 20.100 (8b). The addition of 0.015% w / v tropicamide improves near visual acuity to 20.25 (9a) and reduces the decrease in distance visual acuity to 20.55 (9b), although in some cases some irregular astigmatism is induced (a slightly blotchy area in the reading field). Topical application of 1.55% w / v aceclidine in saline improves near visual acuity to 20.40 over a 6-hour prolonged period (10a) without affecting baseline distance visual acuity (10b). 10c and 10d show the effect of administration of aceclidine in a carrier consisting of 5.5% w / v 2-hydroxypropyl β-cyclodextrin, 0.75% w / v CMC (1%=2,500 centipoise), 0.25% w / v NaCl, and 0.01% w / v BAK. As seen in 10c, the carrier enhances the effective effect of aceclidine to obtain near visual acuity of 20.20 or higher. As seen in 10d, a similar improvement in distance visual acuity occurs. 10e and 10f show the effect of adding 0.042% w / v tropicamide to aceclidine in the carrier. As seen in 10e, near visual acuity improves to 20.15 with a rapid onset of maximum visual acuity. As seen in 10f, a similar improvement in distance visual acuity occurs. In summary, FIG. 1 shows that aceclidine can temporarily correct near visual acuity in presbyopic subjects without affecting baseline distance visual acuity. Similar results were obtained with the addition of a cycloplegic drug such as tropicamide.
[0167] The present invention further relates to ophthalmic compositions further comprising a tonicity adjusting agent and a preservative.
[0168] The tonicity adjuster may be, but is not limited to, a salt such as sodium chloride ("NaCl"), potassium chloride, mannitol or glycerin, or another pharma- ceutically or ophthalmically acceptable tonicity adjuster. In certain embodiments, the tonicity adjuster is 0.037% w / v NaCl.
[0169] Preservatives that may be used in the present invention include, but are not limited to, benzalkonium chloride ("BAK"), sorbic acid, oxychloro complexes, citric acid, chlorobutanol, thimerosal, phenylmercuric acetate, disodium ethylenediaminetetraacetate, phenylmercuric nitrate, perborate, or benzyl alcohol. In a preferred embodiment, the preservative is BAK, sorbic acid, oxychloro complexes, or a combination thereof. In an even more preferred embodiment, the BAK is at a concentration of about 0.001% to about 1.0% w / v, more preferably at a concentration of about 0.007%, 0.01% or 0.02% w / v. In another preferred embodiment, the preservative is perborate at a concentration of 0.01% to about 1.0% w / v, more preferably at a concentration of about 0.02% w / v.
[0170] Various buffers and means for adjusting pH can be used to prepare the ophthalmic composition of the present invention. Such buffers include, but are not limited to, acetate buffer, citrate buffer, phosphate buffer, and borate buffer. It is understood that an acid or base can be used to adjust the pH of the composition, preferably to a concentration of 1 to 10 mM, more preferably about 3 mM or 5 mM, as needed. In a preferred embodiment, the pH is about 4.0 to about 8.0, and in a more preferred embodiment, the pH is about 5.0 to about 7.0.
[0171] The present invention further relates to an ophthalmic composition further comprising an antioxidant. Antioxidants that can be used with the present invention include, but are not limited to, disodium ethylenediaminetetraacetate at a concentration of about 0.005% w / v to about 0.50% w / v, citrate at a concentration of about 0.01% w / v to about 0.3% w / v, dicalcium diethylenetriaminepentaacetate ("Ca2DTPA") at a concentration of about 0.001% w / v to about 0.2% w / v, preferably about 0.01% w / v Ca2DTPA, which can be formulated by adding 0.0084% w / v Ca(OH)2 and 0.0032% w / v pentetic acid to the formulation and slowly mixing. Further combinations of antioxidants can be used. Other antioxidants that can be used with the present invention include those well known to those skilled in the art, such as ethylenediaminetetraacetic acid at a concentration of about 0.0001% w / v to about 0.015% w / v.
[0172] It is a surprising and unexpected discovery that the topical formulation of the present invention, particularly one of the preferred embodiments comprising 1.35% w / v to 1.55% w / v aceclidine; 5.5% w / v polyoxyl 40 stearate; 0.80% w / v CMC; 0.037% w / v NaCl; 0.015% w / v EDTA; 0.007% w / v BAK; and 5 mM phosphate buffer at pH 7.0, provides significantly extended contact lens wear and comfort after a single daily topical instillation. A single daily use of the preferred embodiment allows subjects with dry eye to sleep in their lenses for as long as a week, whereas previously they would have to remove and clean or replace their contact lenses after even one night, due to blurred vision and film coating (see Example 7).
[0173] In a preferred embodiment, the ophthalmic compositions of the present invention comprise aceclidine, a cryoprotectant, optionally a cycloplegic agent, a non-ionic surfactant at a concentration of about 1% to about 5% w / v, and a viscosity agent at a concentration of about 0.75% to about 1.6% w / v, preferably about 1.25% to about 1.5% w / v.
[0174] The following exemplary embodiments are provided for illustrative purposes only and are not meant to limit the invention in any way.
[0175] <Representative embodiment> In one embodiment, the ophthalmic composition comprises: Aceclidine at a concentration of about 1.75% w / v; and Mannitol at a concentration of approximately 2.5% w / v.
[0176] In another embodiment, the ophthalmic composition comprises: aceclidine at a concentration of about 1.75% w / v; Mannitol at a concentration of about 2.5% w / v; and Tropicamide at a concentration of approximately 0.02% w / v.
[0177] In another embodiment, the ophthalmic composition comprises: aceclidine at a concentration of about 1.75% w / v; mannitol at a concentration of about 2.5% w / v; Polysorbate 80 at a concentration of approximately 5.0% w / v; carboxymethylcellulose at a concentration of about 1.4% w / v; BAK at a concentration of about 0.015% w / v; and Phosphate buffer at a concentration of about 3 mM, Here, the pH is about 5.
[0178] In another embodiment, the ophthalmic composition comprises: aceclidine at a concentration of about 1.75% w / v; mannitol at a concentration of about 2.5% w / v; Polysorbate 80 at a concentration of approximately 0.5% w / v; NaCl at a concentration of about 0.10% to about 0.50% w / v; Carbopol® 940 at a concentration of about 0.95% w / v; BAK at a concentration of about 0.01% w / v; and Phosphate buffer at a concentration of about 3 mM, Here, the pH is about 5.
[0179] In another embodiment, the ophthalmic composition comprises: aceclidine at a concentration of about 1.75% w / v; mannitol at a concentration of about 2.5% w / v; Polysorbate 80 at a concentration of approximately 2.0% w / v; NaCl at a concentration of approximately 0.50% w / v Carbopol® 940 at a concentration of about 1.5% w / v; BAK at a concentration of about 0.015% w / v; and Phosphate buffer at a concentration of about 3 mM, Here, the pH is about 5.25.
[0180] In another embodiment, the ophthalmic composition comprises: aceclidine at a concentration of about 1.75% w / v; mannitol at a concentration of about 2.5% w / v; Polysorbate 80 at a concentration of approximately 0.25% w / v; NaCl at a concentration of approximately 0.1% w / v; Boric acid at a concentration of about 0.12% w / v; Carbopol® 940 at a concentration of about 0.95% w / v; and BAK at a concentration of approximately 0.015% w / v; Here, the pH is about 5.
[0181] In another embodiment, the ophthalmic composition comprises: aceclidine at a concentration of about 1.75% w / v; mannitol at a concentration of about 2.5% w / v; Polysorbate 80 at a concentration of approximately 0.50% w / v; NaCl at a concentration of approximately 0.05% w / v; Boric acid at a concentration of about 0.2% w / v; Carbopol® 940 at a concentration of about 0.95% w / v; BAK at a concentration of about 0.01% w / v; and Phosphate buffer at a concentration of about 3 mM, Here, the pH is about 5.
[0182] In another embodiment, the ophthalmic composition comprises: aceclidine at a concentration of about 1.75% w / v; mannitol at a concentration of about 2.5% w / v; Polysorbate 80 at a concentration of approximately 0.1% w / v; Boric acid at a concentration of about 0.2% w / v; Carbopol® 940 at a concentration of about 0.9% w / v; BAK at a concentration of about 0.05% w / v; and Phosphate buffer at a concentration of about 3 mM, Here, the pH is about 5.
[0183] In another embodiment, the ophthalmic composition comprises: aceclidine at a concentration of about 1.75% w / v; mannitol at a concentration of about 2.5% w / v; Polysorbate 80 at a concentration of approximately 0.1% w / v; NaCl at a concentration of approximately 0.1% w / v; Boric acid at a concentration of about 0.12% w / v; Carbopol® 940 at a concentration of about 0.95% w / v; BAK at a concentration of about 0.01% w / v; and Phosphate buffer at a concentration of about 3 mM, Here, the pH is about 5.
[0184] In another embodiment, the ophthalmic composition comprises: aceclidine at a concentration of about 1.75% w / v; Tropicamide at a concentration of approximately 0.01% w / v; mannitol at a concentration of about 2.5% w / v; Polysorbate 80 at a concentration of approximately 5.0% w / v; CMC at a concentration of about 1.4% w / v; BAK at a concentration of about 0.015% w / v; and Phosphate buffer at a concentration of about 3 mM, Here, the pH is about 5.
[0185] In another embodiment, the ophthalmic composition comprises: aceclidine at a concentration of about 1.75% w / v; Tropicamide at a concentration of approximately 0.02% w / v; mannitol at a concentration of about 2.5% w / v; Polysorbate 80 at a concentration of approximately 0.25% w / v; NaCl at a concentration of approximately 0.1% w / v; Boric acid at a concentration of about 0.12% w / v; Carbopol® 940 at a concentration of about 0.95% w / v; and BAK at a concentration of approximately 0.01% w / v. Here, the pH is about 5.
[0186] In another embodiment, the ophthalmic composition comprises: aceclidine at a concentration of about 1.75% w / v; Tropicamide at a concentration of approximately 0.015% w / v; mannitol at a concentration of about 2.5% w / v; Polysorbate 80 at a concentration of approximately 0.75% w / v; NaCl at a concentration of approximately 0.05% w / v; Boric acid at a concentration of about 0.2% w / v; Carbopol® 940 at a concentration of about 0.95% w / v; BAK at a concentration of about 0.01% w / v; and Phosphate buffer at a concentration of approximately 3 mM. Here, the pH is about 5.
[0187] In another embodiment, the ophthalmic composition comprises: aceclidine at a concentration of about 1.75% w / v; Tropicamide at a concentration of approximately 0.025% w / v; mannitol at a concentration of about 2.5% w / v; Polysorbate 80 at a concentration of approximately 0.1% w / v; Boric acid at a concentration of about 0.2% w / v; Carbopol® 940 at a concentration of about 0.9% w / v; BAK at a concentration of about 0.05% w / v; and Phosphate buffer at a concentration of approximately 3 mM. Here, the pH is about 5.
[0188] In another embodiment, the ophthalmic composition comprises: aceclidine at a concentration of about 1.75% w / v; Tropicamide at a concentration of approximately 0.02% w / v; mannitol at a concentration of about 2.5% w / v; Polysorbate 80 at a concentration of approximately 0.1% w / v; NaCl at a concentration of approximately 0.1% w / v; Boric acid at a concentration of about 0.12% w / v; Carbopol® 940 at a concentration of about 0.95% w / v; BAK at a concentration of about 0.01% w / v; and Phosphate buffer at a concentration of approximately 3 mM. Here, the pH is about 5.
[0189] In another embodiment, the ophthalmic composition comprises: aceclidine at a concentration of about 1.75% w / v; Tropicamide at a concentration of approximately 0.040% w / v; Polyoxyl 40 stearate at a concentration of about 5.0% w / v; mannitol at a concentration of about 2.5% w / v; Acetate or phosphate buffer at a concentration of about 3.0 mM; and BAK at a concentration of approximately 0.01% w / v; wherein the composition has a pH of about 4.75.
[0190] In another embodiment, the ophthalmic composition comprises: aceclidine at a concentration of about 1.55% w / v; Tropicamide at a concentration of approximately 0.040% w / v; Polyoxyl 40 stearate at a concentration of about 5.0% w / v; citric acid monohydrate at a concentration of approximately 0.1% w / v; mannitol at a concentration of about 4.0% w / v; Carbopol® 940 at a concentration of 0.09% w / v; and Acetate or phosphate buffer at a concentration of about 3.0 mM; wherein the composition has a pH of about 5.0.
[0191] In another embodiment, the ophthalmic composition comprises: Aceclidine at a concentration of about 1.50% w / v; Tropicamide at a concentration of approximately 0.042% w / v; Polyoxyl 40 stearate at a concentration of about 5.5% w / v; mannitol at a concentration of about 2.5% w / v; phosphate buffer at a concentration of about 3.0 mM; Carbopol® 940 at a concentration of about 0.85% w / v; and BAK at a concentration of approximately 0.01% w / v; wherein the composition has a pH of about 4.75.
[0192] In another embodiment, The ophthalmic composition comprises: aceclidine at a concentration of about 1.45% w / v; Tropicamide at a concentration of approximately 0.042% w / v; Polyoxyl 40 stearate at a concentration of about 5.5% w / v; citric acid monohydrate at a concentration of approximately 0.1% w / v; Acetate buffer at a concentration of about 3.0 mM; and Carbopol® 940 at a concentration of about 0.75% w / v; wherein the composition has a pH of about 4.75.
[0193] In another embodiment, the ophthalmic composition comprises: aceclidine at a concentration of about 1.45% w / v; Tropicamide at a concentration of approximately 0.042% w / v; Polyoxyl 40 stearate at a concentration of about 5.5% w / v; mannitol at a concentration of about 2.0% w / v; citric acid monohydrate at a concentration of approximately 0.1% w / v; Phosphate buffer at a concentration of about 3.0 mM; and Carbopol® 940 at a concentration of about 1.0% w / v; wherein the composition has a pH of about 4.75.
[0194] In another embodiment, the ophthalmic composition comprises: aceclidine at approximately 1.75% w / v; mannitol at approximately 2.5% w / v; Approximately 2.75% w / v polysorbate 80; and Approximately 1.25%; 1.0% to 1.80% w / v hydroxypropyl methylcellulose (depending on molecular weight).
[0195] In another embodiment, the ophthalmic composition comprises: aceclidine at approximately 1.75% w / v; about 0.005% to about 0.011% tropicamide; mannitol at approximately 2.5% w / v; Approximately 2.75% w / v polysorbate 80; and Approximately 1.25%; 1.0% to 1.80% w / v hydroxypropyl methylcellulose (depending on molecular weight).
[0196] In another embodiment, the ophthalmic composition comprises: aceclidine at approximately 1.75% w / v; Tropicamide at approximately 0.010% w / v; mannitol at approximately 2.5% w / v; Polysorbate 80 at approximately 5.0% w / v; Carboxymethylcellulose high viscosity at about 1.40% w / v; Approximately 3mM phosphate buffer; and Approximately 0.010% BAK = as a preservative, at a pH of approximately 5.0.
[0197] In another embodiment, the ophthalmic composition comprises: aceclidine at approximately 1.75% w / v; Tropicamide at approximately 0.006% w / v; mannitol at approximately 2.5% w / v; Approximately 2.5% w / v polysorbate 80; Approximately 1.25%; 1.0% to 1.80% w / v hydroxypropyl methylcellulose (depending on molecular weight); Approximately 3mM phosphate buffer; and Approximately 0.020% BAK = as a preservative, at a pH of approximately 5.0.
[0198] In another embodiment, the ophthalmic composition comprises: aceclidine at approximately 1.75% w / v; Tropicamide at approximately 0.006% w / v; mannitol at approximately 2.5% w / v; Approximately 2.5% w / v polysorbate 80; Approximately 1.25%; 1.0% to 1.80% w / v hydroxypropyl methylcellulose (depending on molecular weight); Approximately 3mM phosphate buffer; About 0.50% w / v NaCl; and Approximately 0.020% BAK = as a preservative, at a pH of approximately 5.0.
[0199] In another embodiment, the ophthalmic composition comprises: aceclidine at approximately 1.75% w / v; mannitol at approximately 2.5% w / v; Polysorbate 80 at approximately 3.5% w / v; Approximately 1.25%; 1.0% to 1.80% w / v hydroxypropyl methylcellulose (depending on molecular weight); Approximately 3mM phosphate buffer; About 0.50% w / v NaCl; and About 0.020% BAK or 0.15% sorbic acid as preservatives, at a pH of about 5.0.
[0200] In another embodiment, the ophthalmic composition comprises: aceclidine at approximately 1.75% w / v; mannitol at approximately 2.5% w / v; Approximately 3.5% w / v polysorbate 80; and Approximately 1.25%; 1.0% to 1.80% w / v hydroxypropyl methylcellulose (depending on molecular weight); In another embodiment, the ophthalmic composition comprises: aceclidine at approximately 1.75% w / v; mannitol at approximately 2.5% w / v; Polysorbate 80 at approximately 3.5% w / v; Approximately 1.25%; 1.0% to 1.80% w / v hydroxypropyl methylcellulose (depending on molecular weight); and One or more excipients selected from the group consisting of about 0.50% w / v sodium chloride, about 0.02% w / v benzalkonium chloride, about 0.10% w / v sorbate, about 0.01% w / v ethylenediaminetetraacetic acid (EDTA), and 0.10% w / v citric acid.
[0201] In another embodiment, the ophthalmic composition comprises: aceclidine at approximately 1.75% w / v; mannitol at approximately 2.5% w / v; Tropicamide at approximately 0.01% w / v; Approximately 0.1% w / v sodium citrate, anhydrous; Approximately 0.02% w / v benzalkonium chloride; Approximately 0.12% w / v sorbic acid; Approximately 0.1% w / v edetate disodium dihydrate; Approximately 4.0% w / v polysorbate 80; and Hydroxypropyl methylcellulose at about 1.25% w / v; Here, the pH is about 5.0.
[0202] In another embodiment, the ophthalmic composition comprises: aceclidine at approximately 1.75% w / v; mannitol at approximately 2.5% w / v; Tropicamide at approximately 0.01% w / v; Approximately 0.1% w / v sodium citrate, anhydrous; Approximately 0.02% w / v benzalkonium chloride; Approximately 0.1% w / v sorbic acid; EDTA at approximately 0.1% w / v; Approximately 3.5% w / v polysorbate 80; and Approximately 1.25%; 1.0% to 2.25% w / v hydroxypropyl methylcellulose (depending on molecular weight); Here, the pH is about 5.0.
[0203] In another embodiment, the ophthalmic composition comprises: aceclidine at approximately 1.75% w / v; mannitol at approximately 2.5% w / v; Tropicamide at approximately 0.01% w / v; Approximately 3mM phosphate buffer; Approximately 0.02% w / v benzalkonium chloride; Approximately 0.1% w / v sorbic acid; Approximately 0.1% w / v citrate; Approximately 3.5% w / v polysorbate 80; and Approximately 1.25%; 0.25% to 2.25% w / v hydroxypropyl methylcellulose (depending on molecular weight); Here, the pH is about 5.0.
[0204] In another embodiment, the ophthalmic composition comprises: Aceclidine at a concentration of 1.5% w / v, mannitol at a concentration of 2.5% w / v.
[0205] In another embodiment, the ophthalmic composition comprises: Aceclidine at a concentration of 1.55% w / v, mannitol at a concentration of 2.5% w / v.
[0206] In another embodiment, the ophthalmic composition comprises: Aceclidine at a concentration of 1.6% w / v, mannitol at a concentration of 2.5% w / v.
[0207] In another embodiment, the ophthalmic composition comprises: Aceclidine at a concentration of 1.65% w / v, mannitol at a concentration of 2.5% w / v.
[0208] In another embodiment, the ophthalmic composition comprises: Aceclidine at a concentration of 1.7% w / v, mannitol at a concentration of 2.5% w / v.
[0209] In another embodiment, the ophthalmic composition comprises: Aceclidine at a concentration of 1.75% w / v, mannitol at a concentration of 2.5% w / v.
[0210] In another embodiment, the ophthalmic composition comprises: Aceclidine at a concentration of 1.80% w / v, mannitol at a concentration of 2.75% w / v, and Carbopol® 940 at a concentration of 0.09% w / v.
[0211] In another embodiment, the ophthalmic composition comprises: Aceclidine at a concentration of 1.48% w / v, mannitol at a concentration of 1.5% w / v, and Carbopol® 940 at a concentration of 0.50% w / v.
[0212] In another embodiment, the ophthalmic composition comprises: Aceclidine at a concentration of 1.80% w / v, mannitol at a concentration of 2.5% w / v, and Carbopol® 940 at a concentration of 0.9% w / v.
[0213] The following examples are provided for illustrative purposes only and are not intended to limit the invention in any way. EXAMPLES
[0214] Example 1: Effect of Acetidine on Vision in Subjects Aged 47 to 67 Table 1 demonstrates the effect on the near focus power of presbyopic subjects before and after ophthalmic administration of compositions containing aceclidine. Each composition contained aceclidine at the indicated concentrations as well as 5.5% w / v HPβCD, 0.75% w / v CMC, 0.25% w / v NaCl, and 0.01% w / v BAK. Additionally, the compositions administered to subjects 4 and 5 contained 0.125% w / v tropicamide. Because aceclidine is an enantiomer, clinical efficacy may vary with different ratios. For this study, the approximate 50:50 ratio of stereoisomers was measured and best determined by polarimetry.
[0215] [Table 1]
[0216] As can be seen in Table 1, all subjects had less than perfect near vision (20.20) in both the left and right eyes (object 15 inches from the eye), and most subjects had less than perfect distance vision before administration of the composition. After administration of the composition, all subjects experienced an improvement in their near vision that lasted between 7 and 12 hours. Surprisingly, the majority of subjects also experienced an improvement in their distance vision during the same time period. Even more surprising was the near point improvement, which was much closer than the 16 inches typically required for comfortable reading, in some cases about 8.5 inches, which is more commonly seen in individuals under 30. The addition of the cycloplegic agent tropicamide had no additive or deleterious effects on the vision correction.
[0217] Example 2: Effect of aceclidine and tropicamide concentrations
[0218] [Table 2]
[0219] Abbreviations: (C) indicates corrected vision, (m) indicates minutes, (hr) indicates hours, mm indicates millimeters, BD indicates baseline distance visual acuity; BN indicates baseline near visual acuity, BP indicates baseline pupil size, OD indicates right eye; OS indicates left eye, and OU indicates both eyes.
[0220] All percentages are w / v. "pt" reflects the size of the marking material, with 4 being equivalent to 20 / 20 vision and 3 being equivalent to 20 / 15 vision.
[0221] "Time" refers to the duration of the effect.
[0222] As can be seen in Table 2, aceclidine at a concentration of at least 1.1% w / v was able to reduce pupil size to 1.63 mm one hour after topical instillation, resulting in correction of near and distance vision for at least 10 hours. Reducing the concentration of aceclidine to 0.75% w / v (formulation #3) reduced the miotic effect to 2.0-2.5 mm after one hour, and vision correction lasted only 6.5 hours. The addition of 0.03% w / v brimonidine reduced ocular redness (without brimonidine, 4 out of 4, not shown) to 1.5 out of 4 within 30 minutes after topical instillation, which was maintained throughout the time vision was corrected. Switching the non-ionic surfactant to HPβCD (formulations #2-6) further reduced ocular redness. Reducing the concentration of aceclidine to 0.75% w / v (formulation #3) further reduced ocular redness, but also reduced the duration of visual correction for that formulation, as noted above.
[0223] Supraorbital rim pain and stinging in the eye was prominent in Formulations #1-3 with a pain level of 2 out of 4, accompanied by mild nausea, upset stomach and fatigue. Surprisingly, the addition of the cycloplegic agent tropicamide reduced the supraorbital rim pain and stinging to 0.5 out of 4 and 0 out of 4, respectively, with the supraorbital rim pain dissipating after 60 minutes (Formulation #4). Furthermore, increasing the concentration of aceclidine to 1.1% w / v restored corrected vision for a longer duration as seen in Formulations #1-2 without increasing ocular hyperemia. However, re-topical instillation of Formulation #4 at the end of the 10 hour period caused significant supraorbital rim pain. Topical instillation of Formulations #5 (OD) and (OS), along with the increase in tropicamide concentration following Formulation #4, alleviated the supraorbital rim pain experienced with the reintroduction of Formulation #4. At the end of the effective duration of Formulation #5, a third topical instillation of Formulation #5 again led to significant supraorbital rim pain. Again, increasing the concentration of tropicamide in Formulation #6 was able to overcome the supraorbital rim pain. Additionally and unexpectedly, tropicamide had no effect on pupil constriction or visual correction, despite being a cycloplegic agent. Surprisingly, the addition of tropicamide resulted in an extended duration of optimal pupil size constriction.
[0224] Formulation #7 was administered to determine the effect of brimonidine on pupil constriction. Administration of Formulation #7 produced a very slight reduction in pupil constriction to 1.70 mm with distance and near vision improvements identical to those of Formulation #5. 2-3+ conjunctival injections were allowed.
[0225] All baseline vision data was based on vision corrected with distance contact lenses. Near vision was perceived by the subject to project from 8 inches horizontally 1.5 hours after induction. A Marco Autorefractor with an infrared camera and on-board pupil calibration scale was used for all pupil size measurements. Once an image was selected, it remained on the screen, allowing for accurate calibration.
[0226] Example 3: Effect of concentration of aceclidine, brimonidine, guanfacine, fadolmidine, tropicamide and additives
[0227] [Table 3]
[0228] All percentages are w / v. Scores are out of 4 for nasal congestion, stinging initial, stinging, 3 min, congestion initial, congestion 15 min, whitening, pain and overall.
[0229] "pt" reflects the size of the print material, with 4 being equivalent to 20 / 20 vision and 3 being equivalent to 20 / 15 vision.
[0230] Baseline visual acuity was 20.20 in both eyes for distance; 20.70 in the unaided right eye for near; and 20.80 in the left eye for near (maximum 16 inches).
[0231] D / C represents discontinuation after eye wash due to intolerable stinging.
[0232] Aceclidine at a concentration of 1.55% w / v was able to reduce pupil size to about 1.63 mm 30 minutes after topical instillation and provided corrected near and distance visual acuity to 20.20 or better for at least 6 hours, with a notable effect lasting about 7.5 hours, as seen in Table 3. Reducing the concentration of aceclidine to 1.25% w / v (not shown) provided useful near visual acuity improvement to about 20.25-20.30, but was not as effective as the alkaline pH at the higher dose range provided more rapid onset, longer duration, and greater effect. The addition of brimonidine at 0.037% w / v reduced ocular hyperemia to baseline (without brimonidine, 4 out of 4, not shown) within 15 minutes after topical instillation, which was maintained for most of the time vision was corrected. The addition of glycerin 0.10% w / v significantly reduced stinging. The addition of poloxamer 188 0.05% w / v and polyoxyl 40 stearate 0.05% w / v instead, however, further reduced the initial stinging but was more viscous. The combination of poloxamer 188 0.1% w / v at pH 6.5 with glycerin 0.1% w / v significantly reduced onset, duration, comfort and efficacy. AB11T, which does not contain glycerin, poloxamer 188, or polyoxyl 40 stearate, resulted in substantial stinging and discontinuation of the experiment with flushing the eye immediately after topical instillation. Substituting guanfacine 0.037% w / v in AB12T for brimonidine resulted in minimal initial hyperemia with prolonged hypochromia and some whitening, and appears to provide the best overall cosmetic effect, although a slightly higher aceclidine concentration is required for optimal effect.
[0233] All baseline visual data was based on vision corrected with distance contact lenses. Near visual acuity was perceived by subjects to be 8" to 10" projected horizontally 30 minutes after infusion of AB4T and AB6T.
[0234] AB4T and AB6T were repeated with both eyes monocularly and binocularly. Substantial improvement in depth perception, near visual acuity to 3pt (0.15) and near distance (8 inches, 20.20) was noted when both eyes were treated versus monocular treatment. Monocular treatment resulted in a worsening of vision with both eyes open versus testing only the treated eye.
[0235] Example 4: Effect of concentration of aceclidine, brimonidine, tropicamide and additives
[0236] [Table 4]
[0237] As seen in Table 4, in formulations #8-9, increasing brimonidine to 0.42% w / v resulted in a reduction in congestion to 0.5, while a CMC of 0.75% w / v resulted in a watery consistency. Unexpectedly, in formulations #10-11, increasing the CMC from 0.75% w / v to the range of 0.80% w / v to 0.87% w / v and increasing NaCl from 0.25% w / v to 0.75% w / v resulted in a thicker consistency and an increase in residence time from 7 hours to 10-12 hours, reducing the amount of drug drained into the nasolacrimal duct. This reduced drug delivery to the nasal passage results in less nasal congestion.
[0238] In formulations #13-18, a reduction in the amount of aceclidine from 1.61% w / v to 1.53% w / v resulted in a pupil size range of 1.8-2.0 mm. Haze as a result of pupil restriction decreased linearly from 1.5 to 0.5 with the reduction in the amount of aceclidine. Specifically, 1.8-2.0 mm pupils allowed in 41% more light than 1.5-1.7 mm pupils. Surprisingly, 1.8-2.0 mm pupils had a near depth increase of 1.75 D. This is a loss of only 0.25 D from the beneficial 2.00 D seen in the 1.5-1.7 mm range. Thus, the 1.80mm to 2.0mm range produced 41% more light while also allowing the full benefit of increased near vision in individuals under age 60; whereas, individuals over age 60 also experienced the full computer benefit and a somewhat increased near vision benefit.
[0239] Increasing the tropicamide concentration from 0.042% w / v (formulations #8-#11) to 0.044% w / v (formulations #13-#18) resulted in a reduction in pain to negligible amounts. The degree of pain may also be correlated with the age of the individual. For individuals such as those under 45 years of age, an increase in the tropicamide concentration to the range of 0.046% w / v to 0.060% w / v may be preferable.
[0240] Additionally, Table 4 shows the unexpected results seen with formulations #13 and #17, where increasing NaCl from 0.25% w / v to the range of 0.50% w / v to 0.75% w / v resulted in an acceptable hyperemia score of only 1.0, even without the addition of the hypotensive agent brimonidine.
[0241] Formulations #15, #16, and #17 each earn a maximum overall rating of 5 by combining the following benefits: (1) a reduced aceclidine concentration to improve the amount of light produced without significantly affecting the near vision benefits seen in formulations #8-#12; (2) an increased NaCl concentration resulting in further reduction in hyperemia even in the absence of brimonidine; and (3) an increased CMC concentration resulting in a longer residence time on the eye.
[0242] Formula #19 is an excellent alternative for the minority of individuals who are high responders to Formulas #15-#17 and who get significant haze with 1.53% w / v aceclidine. Formula #20 is an excellent alternative for the minority of individuals who are low responders to Formula #19. Finally, Formula #21 is an excellent alternative for the minority of individuals who are low responders and get an inadequate pupillary response with Formula #20.
[0243] [Example 5] Comparison of the effects of polyoxyl 40 stearate, HPβCD and poloxamer 407
[0244] [Table 5]
[0245] Clinical Protocol Twenty presbyopic patients with perfect distance correction were each given one of the above prescriptions (#22-#23). All patients underwent pre- and post-instillation distance and near visual acuity measurements, Zeiss Visante® (Visante is a registered trademark of Carl Zeiss Meditec AG) optical coherence tomography, axial length and contrast visual acuity testing (i.e., Colenbrander-Michelson 10% Lum target) with the following results: All patients achieved constricted pupils between 1.5mm and 2.20mm; The patient did not experience ciliary pain, ciliary spasm, or induction of accommodation; All patients achieved 20 / 30+ visual acuity or better at 14 inches, were very satisfied with their high contrast near vision results, and had no significant complaints of burning or pain; The duration of effect lasted 6-8 hours in all cases; Binocular testing provided all patients with 1 to 1.5 additional lines of near visual acuity over monocular testing; The final 10 patients were tested at 20 inches (i.e., computer distance, cell phone distance) and all achieved near visual acuity of 20 / 25 or better; Moderately hyperopic (approximately +2.25 sphere) uncorrected presbyopes were very satisfied with their distance vision, which improved to a level of 20 / 25 or better for distance and near vision in the 20 / 30 range; and Uncorrected distance visual acuity often improved for those patients who chose not to routinely correct small refractive errors.
[0246] As seen in Table 5, the use of polyoxyl 40 stearate provides the most comfortable aceclidine formulation with minimal visual blur and hyperemia. To achieve results similar to those of formulation #22, formulation #23 requires a non-ionic surfactant concentration of 10-15% or higher, and formulation #24 requires a non-ionic surfactant concentration of 15-20% or higher. HPβCD induced a color change over time, possibly indicating oxidation. Captisol® (sulfobutyl ether β-cyclodextrin) was substituted with similar findings.
[0247] Example 6. Adjustment of aceclidine concentration in preferred embodiments. Preferred embodiment: Aceclidine 1.35%-1.55% w / v; Polyoxyl 40 stearate 5.5% w / v; NaCl 0.037% w / v; a viscosity agent, preferably Carbopol® 934 or 940 in an amount sufficient to achieve a CMC of 0.80% w / v or a viscosity of about 5 to about 35 cps upon topical instillation, e.g., Carbopol® 940 at a concentration of about 0.09% to about 1.0% w / v; BAK 0.015% w / v; and About 3 to about 10 mM phosphate, citrate, citrophosphate, or acetate buffer, wherein the pH is about 4.75 to about 6.0.
[0248] 1.35% w / v aceclidine - Stinging on topical instillation, 0.25 / 4.0 (lasting about 2-5 seconds); Hyperemia induced at 10 min: 1.0-1.5 / 4.0; Hyperemia induced at 30 min: 0.0–0.25 / 4.0; Comfort: Very high. Moisture: Very high, eyes maintain a sensation of improved moistness for most of the 24 hour period following a single topical instillation. Depth of focus distance vision: Excellent. Depth of focus near vision: Excellent.
[0249] In testing the above formulations in several subjects, it was discovered that there was a small range in clinical effectiveness depending on the concentration of aceclidine, with 1.35% to 1.55% w / v aceclidine being preferred, with concentrations of 1.35% w / v and 1.45% w / v providing the desired benefit in most subjects.
[0250] It is further discovered that the clinical efficacy of 1.35% w / v aceclidine can be improved when instilled as follows: 1) Baseline efficacy: 1 drop in each eye. 2) For increased effect: 2 drops in each eye. 3) Greater effect: Repeat 1) above after 2) above. 4) Maximum effect: Repeat step 2) above after step 2).
[0251] Example 7. Use of the preferred embodiment to extend contact lens wear. Preferred embodiment: Aceclidine 1.45%w / v; Polyoxyl 40 stearate 5.5% w / v; NaCl 0.037% w / v; a viscosity agent, preferably Carbopol® 934 or 940 in an amount sufficient to achieve a CMC of 0.80% w / v or a viscosity of about 5 to about 35 cps upon topical instillation, e.g., Carbopol® 940 at a concentration of about 0.09% to about 1.0% w / v; BAK 0.02% w / v; and About 3 to about 10 mM phosphate, citrate, citrate, or acetate buffer, where the pH is about 4.75 to about 6.0.
[0252] As a baseline, subjects who normally wore continuous wear lenses for daily wear only (Air Optix®; Air Optix is a registered trademark of Novartis AG) slept in these lenses overnight. Each morning upon awakening, the subjects' vision was blurred and the contact lenses required cleaning and removal of film and deposits that had formed overnight. On awakening, mean visual acuity for distance: 20.60; mean visual acuity for near vision on the Michelson contrast chart: 20.80.
[0253] The formulation was then instilled as a single dose daily between 7:00 am and 10:00 am for seven consecutive days. The subject wore the Air Optix® lenses all day and slept in them overnight. Upon awakening each morning, the subject's visual acuity at distance was 20.20+; unaided near visual acuity was 20.40 (matching the subject's baseline presbyopia if the subject did not wear lenses overnight and instead inserted them upon awakening).
[0254] Example 8: Comparison of the effects of Polyoxyl 40 Stearate and Captisol® (sulfobutyl ether β-cyclodextrin)
[0255] [Table 6]
[0256] As seen in Table 6, when using polyoxyl 40 stearate as the surfactant, the omission of EDTA results in reduced congestion and the highest overall rating among the polyoxyl 40 stearate compositions (formulas #25 and #26). The addition of cocamidopropyl betaine ("CAPB") further reduces congestion but results in significant pain (formula #31). Replacing polyoxyl 40 stearate with Captisol® (sulfobutyl ether β-cyclodextrin) and adding mannitol achieves similar results in reduced congestion as the addition of CAPB to polyoxyl 40 stearate, but without the associated pain, and results in the highest overall rating among the aceclidine compositions (formula #32). After several weeks, the formulation with Captisol® (sulfobutyl ether β-cyclodextrin) had an orange hue, possibly indicating oxidation.
[0257] Example 9: Preferred cold chain composition composition Acetidine in a concentration of about 1.40% w / v to 1.80% w / v; and Tropicamide at approximately 0.42% w / v; Polyoxyl 40 stearate at approximately 5.5% w / v; Mannitol at a concentration of about 2.5% w / v to 4.5% w / v; Carbomer 940 at a concentration of about 0.09% w / v to about 2.0% w / v; Optionally, a preservative such as BAK at a concentration of about 0.2% w / v; Optionally, citrate at a concentration of about 0.1%; Optionally, a 2 to 100 mM, more preferably a 3 to 5 mM acetate or phosphate buffer; wherein the composition has a pH of about 4.5 to about 5.0; preferably, about 4.75 to about 5.0; and Here, w / v indicates weight per volume.
[0258] The composition as described above was administered to a 62 year old subject. It resulted in a pupil of 1.8-1.9 mm ou, 20.20+ reading vision and 20.20+ distance vision; whereas without Carbomer 940, 2.5% mannitol resulted in reduced efficacy and 4.0% mannitol resulted in no near vision effect. No ciliary spasm or loss of distance vision resulted. Onset was within about 15 minutes. A transient hyperemia of about 1+ out of 4 was noted for about 20 minutes without alpha agonist vasoconstrictor. The presence or absence of BAK had no clinical effect and was used to provide an optional preservative.
[0259] Example 10: Stable aceclidine formulation Compositions tested: Aceclidine at a concentration of about 1.50% w / v; Tropicamide at a concentration of approximately 0.042% w / v; Polyoxyl 40 stearate at a concentration of about 5.5% w / v; mannitol at a concentration of about 2.5% w / v; citrate at a concentration of about 3 mM; wherein the composition has a pH of about 4.75.
[0260] Twenty samples of the above composition were divided equally and stored at 25° C. and 4° C. Prior to storage, the initial concentration of aceclidine was measured using high performance liquid chromatography ("HPLC"). The amount of aceclidine in each solution was calculated by the area under the main peak compared to a reference solution of aceclidine. The samples were then stored for three months. Aceclidine measurements were performed at one month, two months, and three months. The results of the stability study are shown in Table 7.
[0261] [Table 7]
[0262] As can be seen in Table 7, "cold chain storage" or storage of the aceclidine compositions at 2°C to 8°C resulted in a significant increase in the stability of aceclidine at all three time points.
[0263] Example 11: Use of a composition containing little or no cycloplegic agent
[0264] Aceclidine alone causes severe ciliary spasm (pain at the supraorbital rim) and myopic blurring, similar to a migraine headache. These effects are inversely correlated with age, with the highest incidence reported in subjects 40 years of age and the lowest incidence reported in subjects 60 years of age or older. The addition of a cycloplegic reduces the ciliary spasm and the associated pain at the supraorbital rim, migraine, pressure around the eye, or other symptoms of ciliary spasm. Surprisingly, the addition of a cycloplegic does not reduce the myopic effect of aceclidine. However, the addition of 2.5% w / v mannitol reduces the myopic effect of aceclidine. Increasing the concentration of aceclidine overcomes this reduction in myopic effect seen with the addition of mannitol.
[0265] However, surprisingly, the increase in aceclidine does not coincide with an increase in ciliary spasm.More surprisingly, the concentration of cycloplegic drug can be reduced or eliminated in the presence of mannitol without increasing ciliary spasm.Thus, by combining high concentrations of aceclidine with little or no cycloplegic drug in the presence of mannitol, near vision is improved without the side effects of low concentrations of aceclidine and high concentrations of cycloplegic drug.
[0266] Moreover, unexpectedly, the addition of a non-ionic surfactant increases both the quantitative measurement and duration of near vision improvement. This effect is concentration sensitive. In a preferred embodiment, the non-ionic surfactant is at least 1%, preferably at least 2%, more preferably about 1% to about 5%, and most preferably about 5%. For example, polysorbate 80 or polyoxyl 40 stearate at a concentration of about 1% to about 5% w / v results in an improvement of about 1.5 to about 2.0 lines and a duration of about 4 to about 5 hours.
[0267] Without wishing to be bound by any particular theory, it is believed that increasing surfactant concentration may crowd the surface of the cornea, and at optimal concentrations, this crowding results in small, perhaps nanometer diameters, and given the polar nature of the surfactants, where non-ionic is most preferred, this enhances corneal absorption of the trapped highly polar aceclidine molecules.
[0268] Further addition of a viscosity agent by itself does not extend the duration. Surprisingly, the addition of a viscosity agent to a formulation containing optimal ratios of aceclidine, tropicamide, and non-ionic surfactant dramatically improves the duration. For example, a formulation of the present invention containing 1.75% aceclidine, 2.5% mannitol, 0.01% tropicamide, and 5% polysorbate 80 improves near vision in presbyopic patients by about 4 to about 5 hours at up to 3 lines of vision. Addition of 1.4% CMC further increases the improvement in near vision to about 7 hours to about 10 hours. Without wishing to be bound by a particular theory, exceeding the critical micelle threshold significantly enhances penetration through the cornea by reducing the micelle size from micrometers to nanometers. See FIG. 2.
[0269] Examples of compositions containing little or no cycloplegic agent are shown in Table 8 below.
[0270] [Table 8-1]
[0271] [Table 8-2]
[0272] [Table 8-3]
[0273] [Table 8-4]
[0274] [Table 8-5]
[0275] [Table 8-6]
[0276] [Table 8-7]
[0277] [Table 8-8]
[0278] The efficacy indices are shown in Figure 3. Briefly, a score is calculated by multiplying the lines of improvement in near vision by the number of hours the improvement lasts. For example, scores are as follows: 5 corresponds to a +1 line improvement in near vision at 5 hours, 10 corresponds to a +1.5 line improvement at 6.7 hours, 15 corresponds to a 2 line improvement at 7.5 hours, 20 corresponds to a 2.5 line improvement at 8 hours, 25 corresponds to a 3+ line improvement at 8.3 hours, and 35 corresponds to a 3.75+ line improvement at 9 hours.
[0279] As shown by comparing the readings and efficacy indexes at 40 cm relative to baseline for formulations #L33-#L37, formulations containing 1.40% or more aceclidine provide better correction of presbyopia than those containing 1.25% aceclidine. Conversely, lower concentrations of aceclidine improve the overall comfort of the user. The addition of 2.5% mannitol to a formulation containing 1.45% aceclidine improves overall comfort but reduces the presbyopia correction effect. (Compare #L37 with #L47.) This decrease in near vision improvement is exacerbated by the addition of 4.0% mannitol (compare #L47 with #L48). Increasing the aceclidine concentration to 1.65% or 1.75% overcomes the decrease in near vision improvement seen with the addition of mannitol (compare #L47 with #L49 and #L50).
[0280] Furthermore, formulations containing 1.75% aceclidine and 2.5% mannitol show increased efficacy and duration in treating presbyopia, which correlates with an increase in polysorbate 80 to 5.0%, and then inversely correlates with a decrease in CMC from 1.45% to 1.40% (compare formulations #L66 and #L78). The optimal formulations are represented by #L77, #L78, and #L85-#L94, which have the highest reading improvement at 40 cm of visual acuity lines of 3.5-3.75, the highest efficacy index score of 25-34, and the longest duration of 7-9 hours, respectively. The increased efficacy and duration of the #L66-#L78 formulations also correlates inversely with a decrease in tropicamide from 0.0275% to 0.01%. This same trend is shown by the increased efficacy (i.e., readings relative to baseline 40 cm) when comparing #L85 and #L94.
[0281] This data shows that mannitol can effectively reduce the ciliary spasm caused by aceclidine and reduce the need for cycloplegics such as tropicamide. Furthermore, this data shows that the addition of a non-ionic surfactant and a viscosity agent can further increase the effectiveness and duration of a composition containing aceclidine, mannitol, and low tropicamide. This data also shows that the use of a cycloplegic in an aceclidine composition containing polysorbate 80 and CMC is most beneficial for correcting presbyopia when the cycloplegic is closer to 0.006% than 0.025%. Finally, this data shows that a composition containing aceclidine and mannitol is sufficient to correct presbyopia with acceptable pain.
[0282] Example 12: Use of additional high tropicamide formulations The following examples are of aceclidine formulations containing greater than 0.03% tropicamide.
[0283] [Table 9] Ciliary spasm scores correspond to: 0 = no discomfort; 0.5=slight sting; 1 = noticeable pressure / discomfort; 2 = pain for less than 30 minutes; 3 = pain for more than 1 hour; and 4=Severe to unbearable pain.
[0284] As shown by a comparison of formulations #L39-#L41 and #L74-#L78 in Table 8, a formulation containing about 1.40% to about 1.45% aceclidine, about 0.035% to about 0.04% tropicamide, about 5.5% polyoxyl stearate, and about 0.75% CMC is not as effective in treating presbyopia as a formulation containing about 1.65% to about 1.75% aceclidine, about 2.5% mannitol, about 5% polysorbate 80, and about 1.40% CMC, but is still effective in most cases. This effectiveness drops off sharply when the tropicamide is increased to about 0.05% to about 0.08% tropicamide.
[0285] [Example 13] Use of a compound containing mannitol Formulation: Acetolysine 1.75%w / v Tropicamide 0.006%w / v Mannitol 2.5%w / v Polysorbate 80 2.75% w / v NaCl 0.5%w / v Hydroxypropyl methylcellulose 0.5%~1.80%w / v Phosphate buffer 3mM pH 5.0, and As a preservative, 0.020% BAK.
[0286] method: Subjects applied two drops of the above formulation to each eye and excess was wiped off the lids and eyelashes.
[0287] result: Within 20 minutes, near vision was improved by approximately 3 lines of acuity with slight dimming. Throughout the day, near vision remained enhanced without loss of distance vision. Additionally, distance vision improved in subjects with a history of mild refractive error. Between 5 and 8 hours, the pupils began to recover slightly, and after a few hours, minimal dimming was no longer observed. Excellent near vision at both onsets, and still slightly improved near vision continued, likely as the pupils began to increase slightly from their minimal size earlier in the day.
[0288] Example 14: Use of preferred embodiments to optimize tropicamide and hydroxypropyl methylcellulose composition Aceclidine 1.75%w / v Tropicamide 0.010%w / v Mannitol 2.50%w / v Polysorbate 803.50%w / v NaCl 0.50%w / v HPMC 1.25%w / v BAK 0.02%w / v Phosphate buffer 3mM pH 5.00
[0289] method Subjects received two drops of the above formulation in each eye, one drop in each eye and a second drop five minutes later.
[0290] result: Comfort, duration, and efficacy were evaluated. Stinging upon instillation and for the first hour was minimal, 0.25 out of 4. Redness during the first hour was also minimal, 0.5 out of 4, rated at 20 minutes. Onset of vision improvement occurred in the first 20-25 minutes after instillation. Baseline near vision (i.e., 40 centimeters) improved by 3.5 lines of vision. Improvement in near vision lasted for 8.5 hours. Comparing this formulation to the formulation in Table 8, the efficacy index score was 29.75. Substitution of 1.80% w / v HPMC with 1.65% w / v HPMC slightly reduced the improvement in near vision to 3.25 lines of vision and slightly reduced duration to just over 6 hours. Comparing this formulation to the formulation in Table 8, the efficacy index score was 19.5.
[0291] Example 15: Use of mannitol-containing compounds with various non-ionic surfactants. composition Table 10 lists the active ingredients, excipients, and their concentrations for compositions containing both test and hypothetical examples of non-ionic surfactants.
[0292] method Subjects instilled two drops of the above formulation into each eye and excess was wiped off the lids and eyelashes.
[0293] result All nonionic surfactants tested showed substantial near vision improvement. Of those tested, only Brij® 35 caused significant corneal irritation, hyperemia, and a resulting shortened duration. Polysorbate 80 and Poly 35 Castor Oil were most preferred, with Polyoxyl 40 Stearate and Poloxamer 407 also performing well. However, Polyoxyl 40 Stearate caused a precipitation reaction with the cellulose viscosity agent, adding other stability issues.
[0294] The comfort and duration of each nonionic surfactant was also tested and is listed in Table 10. Stinging and redness were based on a scale of 0 to 4, with 0 being none and 4 being most severe. Mild to no stinging or redness was observed, with the exception of Brij® 35. Duration of each nonionic surfactant tested was excellent.
[0295] [Table 10]
[0296] Example 16: Use of compounds containing non-ionic surfactants and antioxidants and optimization of their concentrations composition Aceclidine 1.75%w / v Tropicamide 0.010%w / v Mannitol 2.50%w / v Polysorbate 80 4.00% w / v NaCl 0.00%w / v HPMC 1.25% w / v (high MW equivalent to a viscosity of approximately 400 cps units) BAK 0.02%w / v Sorbic acid 0.12%w / v BAK 0.02%w / v EDTA 0.01% Citrate buffer 3mM pH 5.00
[0297] method Two subjects instilled two drops of each of the above formulations in each eye, approximately five minutes apart. result: Comfort, duration, and efficacy were evaluated. Stinging upon instillation and during the first hour was minimal for each subject, lasting approximately 15 seconds, rated at 0.50 out of 4. Redness during the first hour was also minimal for each subject, rated at 0.25 out of 4 at 20 minutes. Onset of visual acuity improvement occurred in the first 20-25 minutes after instillation. For subject 1, baseline near visual acuity (40 centimeters) improved by 4.0-4.25 lines of visual acuity, which lasted for 11.5 hours. For subject 2, baseline near visual acuity improved by 3.5 lines of visual acuity, which lasted for 9.5 hours. Efficacy index scores were 47.38 and 33.25, the highest scores of any formulation.
[0298] Example 17: Aceclidine composition for cold chain storage (hypothetical example)
[0299] [Table 11-1]
[0300] [Table 11-2]
[0301] [Table 11-3]
[0302] method Aceclidine cold chain storage compositions CS#1-5 and 11-20 were each filled into vials under nitrogen overlay followed by nitrogen purging of the remaining headspace. CS#6-10 were each filled into vials under ambient air and headspace. One vial of each composition was stored at 25 degrees Celsius and the other was stored at 5 degrees Celsius.
[0303] result
[0304] [Table 12-1]
[0305] [Table 12-2]
[0306] As shown in FIG. 4, CS#3-5 containing 0.10% sodium ascorbate, 0.10% sodium bisulfate, or 0.10% sodium metabisulfite were stable for approximately 2 months at 25 degrees Celsius and for approximately 26 months at 5 degrees Celsius.
[0307] As shown in Table 12, filling the vials under a nitrogen overlay and purging the headspace with nitrogen improved refrigerated stability by 4-5 months. The addition of HPMC improved stability by an additional 3 months; sodium citrate, sodium bisulfate, or sodium metabisulfite by an additional 3 months. Also, the addition of sorbic acid and BAK for an additional 2 months further increased the length of stability. CS#20 improved stability up to 22 months.
[0308] Example 18: Stability of Mylar®-lined pouches The aceclidine formulations of the present invention were placed in containers and then placed in biaxially oriented polyethylene terephthalate lined pouches at -20, 5 and 25°C for up to 3 months. Total related substances of aceclidine were recorded at 1, 2, 3 and 6 months. The results of this study can be seen in Table 13 below.
[0309] Mylar® was used as the source of biaxially oriented polyethylene terephthalate. Mylar is a registered trademark of and available from DuPont Teijin Films US Limited.
[0310] [Table 13]
[0311] As shown in Table 13, the use of a Mylar®-lined pouch helped maintain the efficacy of aceclidine by slowing down the rate of degradation, specifically comparing the total change of 4.46% without the pouch at room temperature (25° C.) to the total change of −0.05% and 0.041% with the pouches at room temperature (25° C.).
Claims
1. A method of stabilizing a composition comprising aceclidine, the method comprising storing the composition in a container having a headspace at a temperature of about 2 degrees Celsius to about 8 degrees Celsius.
2. The method of claim 1 , wherein the composition is filled into a container under an inert gas overlay.
3. The method of claim 2 , wherein the headspace is purged with an inert gas.
4. 10. The method of claim 1, wherein the container comprises a closure and a container, a portion of the closure and a portion of the container being sealed with a leach-resistant material selected from the group consisting of biaxially oriented polyethylene terephthalate, polytetrafluoroethylene, and aluminum foil.
5. 10. The method of claim 1, wherein the container is placed within a second container formed or lined with a leaching-resistant material selected from the group consisting of biaxially oriented polyethylene terephthalate, polytetrafluoroethylene, and aluminum foil.
6. 2. The method of claim 1, wherein the aceclidine is at a concentration of about 0.25% to about 4.0% w / v aceclidine, where w / v indicates weight by total volume of the composition.
7. 10. The method of claim 1, wherein the method provides at least 90% stability of aceclidine for at least 7 months.
8. 6. The method of claim 5, wherein the method provides at least 90% stability of aceclidine for at least 12 months.
9. 10. The method of claim 1, wherein the composition further comprises a viscosity agent, a polysorbate, a cryoprotectant, and a preservative.
10. 10. The method of claim 9, wherein the method provides at least 90% stability of aceclidine for at least 18 months.
11. 10. The method of claim 9, wherein the viscosity agent provides a viscosity of at least 50 centipoise.
12. 10. The method of claim 9, wherein the cryoprotectant is selected from the group consisting of polyols, sugars, alcohols, lower alkanols, lipophilic solvents, hydrophilic solvents, bulking agents, solubilizers, surfactants, antioxidants, cyclodextrins, maltodextrins, colloidal silicon dioxide, polyvinyl alcohol, 2-methyl-2,4-pentanediol, cellobiose, gelatin, polyethylene glycol (PEG), dimethylsulfoxide (DMSO), formamide, antifreeze protein 752, or combinations thereof.
13. 10. The method of claim 9, wherein the preservative is selected from the group consisting of benzalkonium chloride, sorbates, antioxidants, and combinations thereof.
14. 12. The method of claim 11, wherein the antioxidant is selected from the group consisting of sodium ascorbate, sodium bisulfate, sodium metabisulfite, n-acetylcysteine, and combinations thereof.
15. A method for stabilizing a composition comprising aceclidine, a viscosity agent, and a non-ionic surfactant, comprising storing the composition in a container having a headspace at a temperature of about 2°C to about 8°C, the composition being filled into the container under a nitrogen overlay, the headspace being purged with nitrogen, and the composition providing a low shear (1 / sec) viscosity of about 50 to about 1000 centipoise and a high shear (1:1000 / sec) viscosity of about 0.5 centipoise or less.
16. 1. A method comprising stabilizing a composition comprising aceclidine, hydroxypropyl methylcellulose, polysorbate 80, mannitol, sorbate, and an antioxidant selected from the group consisting of sodium ascorbate, sodium bisulfate, sodium metabisulfite, n-acetylcysteine, or combinations thereof, and storing the composition in a container having a headspace at a temperature of from about 2 degrees Celsius to about 8 degrees Celsius, wherein the composition is filled into the container under a nitrogen overlay and the headspace is purged with nitrogen.
17. the aceclidine is at a concentration of about 0.25% to about 4.00% w / v; the hydroxypropyl methylcellulose is at a concentration of about 0.75% to about 1.25% w / v; Polysorbate 80 is at a concentration of about 2% to about 4% w / v; the mannitol is at a concentration of about 2% to about 4% w / v; the sorbate is at a concentration of about 0.10% to about 0.12% w / v and the antioxidant is at a concentration of about 0.10% to about 0.25% w / v; 17. The method of claim 16, wherein w / v indicates weight by total volume of the composition.
18. 20. The method of claim 17, wherein the method provides at least 90% stability of aceclidine for at least 20 months.
19. 20. The method of claim 18, wherein the method provides at least 90% stability of aceclidine for at least 22 months.
20. a) providing a container; b) filling the container with a composition comprising aceclidine under an inert gas overlay; c) purging the head space created during filling step b) with an inert gas; d) placing a lid on the container A container containing aceclidine prepared by the steps comprising:
21. 21. The container of claim 20, wherein the process further comprises storing the container at a temperature of about 2 degrees Celsius to about 8 degrees Celsius.
22. 21. The container of claim 20, wherein the composition further comprises a preservative selected from the group consisting of sorbate, benzalkonium chloride, sodium ascorbate, sodium bisulfate, sodium metabisulfite, n-acetylcysteine, and combinations thereof.
23. 21. The container of claim 20, wherein the composition has a viscosity of at least 50 centipoise.
24. 1. A composition comprising about 0.25% to about 4.0% w / v aceclidine and one or more means for stabilizing the composition selected from the group consisting of: filling the composition into a container under an inert gas overlay and purging the head space created during filling with the inert gas; having a total viscosity of the composition of at least 50 centipoise or more; adding a preservative to the composition selected from the group consisting of sorbate, benzalkonium chloride, sodium ascorbate, sodium bisulfate, sodium metabisulfite, n-acetylcysteine, and combinations thereof, wherein the composition is stored at a temperature of about 2 to about 8° C., and w / v refers to weight by total volume of the composition.
25. 1. A method of stabilizing a composition comprising aceclidine, comprising storing the composition in a container having a headspace at a temperature of about 22° C. to about 25° C. wherein the container comprises a closure and a container, a portion of the closure and a portion of the container being sealed with a leach-resistant material selected from the group consisting of biaxially oriented polyethylene terephthalate, polytetrafluoroethylene, and aluminum foil; and / or The method wherein the container is placed into a second container formed from or lined with biaxially oriented polyethylene terephthalate, polytetrafluoroethylene, and aluminum foil.
26. 26. The method of claim 25, wherein the second container includes a second closure, the second closure providing an airtight seal.
27. 27. The method of claim 26, wherein the hermetic seal is resealable.
Citation Information
Patent Citations
Liquid drug package
JP1987194861A
Package for easily oxidizable substance or component containing the substance
JP1999292151A
Shelf-stable compositions and methods for the treatment of refractive errors in the eye
JP2018517738A
Composition for improving distance vision and treating refractive error of the eye
JP2018517740A
Compositions and methods for the treatment of presbyopia
JP2022504746A
